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PREPARATION AND EVALUATION OF DECONSTRUCTION ANALOGS OF 7-
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Pyranonaphthoquinone lactones have been recently found to be selective inhibitors of the serine-
threonine kinase AKT/PKB. AKT/PKB plays a major role in tumorigenesis, hence these 
compounds have a great potential to act as anti-cancer agents. They act by a novel bioreductive 
alkylation mechanism of inhibition of AKT/PKB.   
In this work, 7-deoxykalafungin, a pyranonaphthoquinone lactone and its deconstruction analogs 
were synthesized. The structural features of the compounds necessary to inhibit AKT1 potently 
and selectively were determined. It was observed that compounds with a pyran ring were more 
xii 
 
 
potent in inhibiting AKT1. Conversely, flexible compounds were found to be weak inhibitors of 
AKT1. Also, presence of a lactone ring was found to be favorable in inhibiting AKT1.
Of the compounds tested, 7-deoxykalafungin was the most potent inhibitor of AKT1 (IC50 = 0.28 
µM against AKT1) and compound 4-61 was the most potent inhibitor of PKA (IC50 = 0.43 µM 
against PKA). 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Protein phosphorylation 
Proteins can be regulated by reversible covalent modifications such as phosphorylation, 
acetylation, hydroxylation, methylation, etc. The most commonly encountered modification is 
phosphorylation (Figure 1) which is carried out by protein kinases.
1
 
 
Figure 1. Frequency of post-translational modifications
1 
Protein kinases are regulatory enzymes that transfer a phosphate group from ATP to the 
substrates resulting in activation or inactivation of the substrates. They require a divalent metal 
ion such as Mg
2+
 for their activity. A total of 518 protein kinases have been found in humans to 
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date.  The residues that are most commonly phosphorylated are serine (~76-90%), threonine 
(~10-20%) and tyrosine (~0.05-4%). The less commonly phosphorylated residues are histidine, 
aspartic acid and glutamic acid. There are 8 major groups of protein kinases AGC (PKA, PKG, 
PKC); CAMK (Ca-Calmodulin dependent protein kinases); CMGC (CDK, MAPK, GSK3, 
CLK); TK (Tyrosine Kinases); TKL (Tyrosine Kinase Like kinases); STE (homologs of yeast 
kinases); RGC (Receptor Guanylate Cyclases) and CK1 (Casein Kinase 1).
2 
 
1.2 AGC kinases  
AGC kinases are a subfamily of protein kinases that have a similar catalytic kinase domain as 
that of cAMP-dependent protein kinase (PKA), cGMP-dependent protein kinase (PKG) and 
protein kinase C (PKC).
3
 To date, 60 human AGC kinases have been found. A general structure 
of an AGC kinase is shown below. (Figure 2) It consists of a large carboxy terminal lobe (C-
lobe) in the activation segment, a small amino terminal lobe (N-lobe), αC helix connecting both 
the lobes, a turn motif and a hydrophobic motif. In order for an AGC kinase to be activated, it 
has to be phosphorylated in two highly conserved motifs – the ‘activation segment’ or ‘T-loop’ 
present in the catalytic domain and ‘hydrophobic motif’ present in the non-catalytic domain. 
Some AGC family members contain a Pleckstrin Homology (PH) domain. In many AGC kinases 
phosphorylation of the ‘turn motif’ helps in maintaining the integrity of the kinase.4 The ‘bilobal 
kinase fold’ affords one molecule of ATP between the N-lobe and the C-lobe which acts as the 
phosphate donor during the phosphorylation reactions.
 5
 The AGC kinases phosphorylate a 
variety of proteins, most of which contain basic residues at the N-terminal position of the 
phosphorylated serine or threonine residues. They play a very important role in various cellular 
functions and are found to be implicated in many diseases such as cancer and diabetes. 
 3 
 
 
 
Figure 2. Structure of catalytic domain of human PKC II in complex with an inhibitor 
“Reprinted with permission from Grodsky, N.; Li, Y.; Bouzida, D.; Love, R.; Jensen, J.; Nodes, 
B.; Nonomiya, J.; Grant, S. Structure of the catalytic domain of human protein kinase C  β II 
complexed with a bisindolylmaleimide inhibitor. Biochemistry. 2006, 45, 13970-13981. 
Copyright 2006, American Chemical Society. 
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1.3 AKT Introduction 
Akt was first identified in 1987 by Stephen Staal in a mouse strain that spontaneously developed 
lymphoma in the thymus caused by a transforming retrovirus.
6 
The viral oncogene was termed v-
Akt. The cellular homolog of this viral oncogene found in humans was termed Akt1 (the first 
identified isoform in humans). AKT exists as three isoforms AKT1 (PKBα), AKT2 (PKBβ) and 
AKT3 (PKBγ) encoded by three separate genes. Akt1 is ubiquitously distributed in many tissues 
and is responsible for growth and survival of cells.
7
 Akt2 is found mainly in adipocytes and 
muscle cells; it is responsible for glucose homeostasis.
8
 Akt3 expression is restricted to brain and 
testes. AKT has an N-terminal PH domain, a kinase (catalytic) domain and a C-terminal 
regulatory region containing a hydrophobic motif. The catalytic domain of AKT is very similar 
to that of other PKA and PKC family members. 
The three isoforms of AKT share different levels of homology in different domains. (Table 1) 
Table 1. Percent sequence similarity between AKT isoforms
9
 
PAIR PH domain LINK region Catalytic domain C-terminal extension 
AKT1/AKT2 80 % 46 % 90 % 66 % 
AKT1/AKT3 84 % 40 % 88 % 76 % 
AKT2/AKT3 76 % 17 % 87 % 70 % 
 
1.3.1 Phosphorylation sites 
The isoforms of Akt have different phosphorylation sites. (Figure 3) The serine and threonine 
residues (shown in red) are necessary for the activation of Akt, whereas the other sites are found 
to be constitutively phosphorylated.
10
 
 5 
 
 
Figure 3. Phosphorylation sites on the isoforms of Akt 
 
1.3.2 Crystal structure of AKT1 
A crystal structure of full-length AKT has not been reported to date. The PH domain and the 
catalytic domains have been crystallized separately. The first crystal structure of AKT1 (1-123 
amino acids bound to phosphoinositol-3,4,5-triphosphate) was reported by Thomas et al. 
11
 
The crystal structure of AKT2 (146-481 amino acids bound to GSK3-peptide and AMP-PNP) 
was reported by Yang et al in 2002.
12
 In this structure, S474 phosphorylation on the hydrophobic 
motif helps in the ordering of αC helix by promoting the interaction between the hydrophobic 
motif and the N-lobe of kinase domain. This αC helix then interacts with the phosphorylated 
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T309 in the activation segment. This results in conformational change and activation of the 
enzyme. 
 
1.4 Regulation of AKT by upstream processes 
AKT is regulated by and regulates a wide range of factors - a few of which are discussed below.  
1.4.1 Positive regulation of Akt 
AKT is positively regulated by a number of factors that result in its phosphorylation. 
1.4.1.1 Phosphatidylinositol 3-Kinase (PI 3-Kinase) mediated activation of AKT/PKB  
It has been found that Akt is activated by PDGFR β (Platelet-Derived Growth Factor Receptor β) 
through PI 3-Kinase.
13
 PDGFR is a tyrosine kinase receptor. Upon stimulation, it undergoes 
dimerization.
14
 This activates its intrinsic kinase activity leading to the autophosphorylation of its 
tyrosine residues Y740 and Y751 which in turn leads to the binding of PI 3-Kinase to its 
phosphorylated tyrosine residues. PI 3-Kinase has a regulatory subunit (p85) and a catalytic 
subunit (p110). When stimulated by the growth factor, PI 3-Kinase binds to the phosphorylated 
tyrosine residues Y740 and Y751 of the growth factor receptor through its regulatory subunit and 
gets activated. Once activated, it phosphorylates inositol residues to form PIP2 and PIP3 through 
its catalytic domain. PIP3 then binds to Akt at its PH domain which results in the translocation of 
Akt to the plasma membrane and its subsequent activation (Figure 4). 
1.4.1.2 Role of Phosphoinositide Dependent Kinases (PDKs) in the activation of AKT/PKB 
It is found that Akt1 is phosphorylated on its serine and threonine residues even before it 
undergoes activation by the growth factors. For instance, S124 and T450 in mouse Akt1 undergo 
phosphorylation constitutively.
15
 This phosphorylation makes Akt more prone to subsequent 
phosphorylations. T308 and S473 residues that lie in the activation loop of the kinase domain 
 7 
 
and in the carboxy terminal of the kinase, respectively, are found to be very crucial in the 
activation of Akt by growth factors. 3-Phosphoinositide Dependent Kinase 1 (PDK1) has been 
found to phosphorylate Akt at its T308 residue. This kinase was cloned and purified  
 
 
Figure 4. Activation of PI 3-Kinase by PDGF 
in 1997.
16
 PDK1 binds with a high affinity to PIP3 through its PH domain’s C-terminus. Some 
studies show that upon stimulation by growth factors, PDK1 is translocated to the plasma 
membrane
17
and phosphorylates Akt. Whereas other studies suggest that PDK1 does not 
translocate upon stimulation by growth factors.
18
 However, very little PDK1 remains bound to 
the plasma membrane in non-stimulated cells. The PDK1 in the plasma membrane might be 
responsible solely for the phosphorylation of Akt and other substrates present in the membrane 
and the one in the cytoplasm might be responsible for the phosphorylation of other cytosolic 
proteins. PDK1 does not phosphorylate S473 by itself.
19
 The kinase that phosphorylates S473 
has been in debate for a very long time. Several kinases have been proposed. Delcommenne et al 
 8 
 
have found that a serine-threonine kinase named Integrin-Linked Kinase 1 (ILK-1) 
phosphorylates S473 in vitro.
20
 Whereas, Balendran et al. suggest that both PDK1 and PDK2 
might be the same enzyme and the ability to phosphorylate S473 and/or T308 specifically 
depends on the interaction of PDK1 with other components within the cell.
21
 They have found 
that the kinase domain of PDK1 interacts with the carboxy terminal region of Protein Kinase C-
Related Kinase (PKN2 or PRK2). This region has been named PDK1-Interacting Fragment 
(PIF). PIF has the same consensus sequence as that of PDK2 with just one difference – the serine 
473 is replaced by an aspartic acid residue. Once PDK1 interacts with PIF, it is converted to an 
enzyme form that phosphorylates both T308 and S473 in Akt/PKB. They have also ruled out the 
possibility of autophosphorylation at S473 residue by Akt itself once T308 is phosphorylated by 
PDK1. (Figure 5) 
P
P
T308
S473
PH
PIP3
Nucleus
T308
S473
PH
PIP3
PDK1
PDK2? ILK-1?
 
Figure 5. Phosphorylation of AKT1 
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But recently, it has been found that S473 is phosphorylated by PI3-Kinase-related Kinase (PIKK) 
super family members - mammalian Target Of Rapamycin Complex 2 (mTORC2)
22 
under 
normal growth conditions and DNA dependent Protein Kinase (DNA-PK) under conditions of 
stress.
23
 AKT1 is phosphorylated constitutively at Thr450 in its turn motif. This is essential for 
the stabilization and the prevention of dephosphorylation of the hydrophobic motif.
4
 
1.4.1.3 Integrin-mediated stimulation of AKT
24
 
Integrins are heterodimeric receptors on the cell surface that are involved in the adhesion, 
differentiation, migration, growth and survival of cells. When a cell gets attached to the 
fibronectin receptors in the extracellular matrix by the action of integrins, the Focal Adhesion 
Kinase (FAK), a tyrosine kinase in the cytoplasm, gets activated by the phosphorylation of its 
tyrosine residue by integrins. This in turn stimulates the interaction of FAK with p85 subunit of 
PI 3-Kinase
25 
resulting in the phosphorylation of PI 3-Kinase and hence its activation. As a 
result, PI 3-Kinase phosphorylates the D3 position of inositol ring to form PI(3,4)P2 and 
PI(3,4,5)P3. This activates the Akt signaling pathway by the binding of phosphoinositides to the 
PH domain of AKT. 
1.4.1.4 B cell Antigen Receptor (BCR) mediated activation of PI 3-Kinase: 
It has been found that the B Cell antigen Receptors (BCR) activate Akt signaling pathway by 
activating PI 3-Kinase.
26
 The role of Akt in the survival of B cells is not exactly known. It might 
play a role in enhancing the protein synthesis in B cells.  
1.4.1.5 Miscellaneous  
Angiotensin II,
27
 hydrogen peroxide,
28
 CD28, CD5, GPCRs, µ receptors have been found to 
activate Akt signaling through PI 3-Kinase. 
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1.4.2 Negative regulation of Akt 
Dephosphorylation is the major means by which Akt is negatively regulated. This is achieved by 
the action of various phosphatases aided by the short half-lives of phosphorylated T308 and S473 
residues. 
 
Figure 6. Dephosphorylation of phosphoinositides 
1.4.2.1 Dephosphorylation by PTEN (Phosphatase and Tensin Homologue deleted on 
chromosome 10) 
PTEN is a tumor suppressor gene present on the human chromosome 10 in the 10q23 region.
29
 It 
is also referred to as MMAC1 (Mutated in Multiple Advanced Cancer 1). PTEN has been found 
to be implicated in many types of human cancers such as glioblastomas, melanomas, etc. It 
contains a catalytic motif homologous to that present in protein tyrosine phosphatases. PTEN has 
been found to be a lipid phosphatase with 3-phosphoinositide specific phosphatase activity.
30
 It 
dephosphorylates PI(3,4,5)P3 to form PI(4,5)P2 (Figure 6). Thus it inhibits PI 3-Kinase activity, 
 11 
 
thereby inhibiting the Akt/PKB pathway.
31
 This inhibition by PTEN is found to affect only the 
basal PKB activity, it does not affect the pathway when Akt is stimulated by growth factors.
30
 
Some other studies have shown that PTEN inhibits the cell migration and focal adhesion by 
causing tyrosine dephosphorylation of FAK, thereby inhibiting FAK.
32
 
1.4.2.2 Dephosphorylation by SHIP (SH (Src Homology)-2 containing Inositol 5′ 
Phosphatase) 
SHIP is a 5′ specific lipid phosphatase that breaks down PI(3,4,5)P3 to PI(3,4)P2. SHIP1 is 
present in hematopoietic cells and SHIP2 is found in non-hematopoietic cells. It has been found 
that in myeloid cells, SHIP inhibits Akt pathway which is stimulated by the growth factors.
33
 
This is in contrast to PTEN which only inhibits the basal activity of Akt/PKB. In myeloid cells, 
when cytokine receptors are stimulated by the cytokines, they get activated and in turn activate 
PI 3-Kinase and induce tyrosine phosphorylation of SHIP. Activation of PI 3-Kinase results in 
the formation of PI(3,4,5)P3. The phosphorylated SHIP is then translocated to the plasma 
membrane by interaction with Shc (Src homology and collagen). In the membrane, SHIP 
dephosphorylates PI(3,4,5)P3 to PI(3,4)P2 (Figure 6). This results in the inactivation of 
Akt/PKB pathway. Aman et al. have reported that SHIP inhibits the activation of Akt/PKB 
pathway in B cells.
34
 
1.4.2.3 PH domain 
PH domain acts as both positive and negative regulator of Akt. In a cell, Akt is present in a 
constitutively inactive state in the cytoplasm due to the interaction between its PH domain and 
the kinase domain.
35
 This intramolecular interaction does not allow the threonine residue to be 
exposed to PDK1, hence it remains unphosphorylated. When 3-phosphoinositides bind to the PH 
 12 
 
domain, the conformation of Akt changes, its activation/catalytic loop is exposed, resulting in the 
phosphorylation of T308 by PDK1.  
 
1.5 Downstream processes of Akt - Cellular functions  
Akt is known to phosphorylate several proteins. In order for a protein to be phosphorylated by 
Akt, it must have the consensus sequence of Arg-X-Arg-Y-Z-Ser/Thr-Hydrophobic and bulky 
residue (where X - any amino acid, Y and Z – small amino acids other than Gly).36 Around a 
thousand proteins in the cell contain this consensus sequence, of which 50 have been 
characterized as AKT substrates till date. These substrates can be classified as: 
1.5.1 Cell cycle progression regulators  
These include Glycogen Synthase Kinase 3β, p21, p27, cyclin D1, etc. 
1.5.1.1 Glycogen Synthase Kinase (GSK) 3α and 3β  
Glycogen synthase is a constitutively active enzyme that is involved in the rate-determining step 
of glycogen synthesis. It exists as two isoenzymes in mammals – α (51 kDa) and β (47 kDa). The 
phosphorylated form of this enzyme is inactive and the non-phosphorylated form is active. GSK3 
is known to phosphorylate four clustered serine residues named 3a – 3d in Glycogen Synthase 
enzyme. This inhibits the GS enzyme. In order for GS to be phosphorylated by GSK3, the 
priming site (the serine residue at +4 position with respect to the target serine residue) on GS has 
to be phosphorylated. This is done by Casein Kinase 2.  
It is found that, in response to insulin
37
 and other growth factors such as Epidermal Growth 
Factor (EGF),
38
 GSK3α is phosphorylated at serine 21 residue and GSK3β is phosphorylated at 
serine 9 residue by Akt/PKB. This inhibits GSK, as a result, glycogen synthase remains in a 
dephosphorylated/active state resulting in the synthesis of glycogen. 
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GSK3 phosphorylates and inhibits many proto-oncogenes such as c-Jun, c-Myc, β-catenin, etc.  
 β-catenin - once phosphorylated by GSK3β, it gets degraded due to the action of the 
proteosome, hence the cell dies. Thus Akt promotes cell survival by inhibiting GSK3β due to 
phosphorylation. 
 c-Jun - it is a part of the transcription factor complex called AP1 (Activator Protein 1). Once 
phosphorylated by GSK3 at 3 residues, it loses its DNA-binding affinity. Hence, the trans-
activation of its effector genes does not occur.
39
 Akt protects the activity of c-Jun by 
inhibiting GSK3. 
 eIF-2B - GSK3 phosphorylates the eukaryotic Initiation Factor-2B in vitro. eIF-2B regulates 
the levels of eIF-2 which plays an important role in translation 
1.5.2 Cell survival/death regulators 
These include Forkhead transcription factors, BAD, caspase-9, p53, etc.  
1.5.2.1 Forkhead transcription factors 
Forkhead transcription factors
40 
such as DAF-16 (in Caenorhabditis elegans); FKHR, FKHR1 
and AFX (in humans) cause apoptosis in cells. They contain a Nuclear Localization Sequence or 
Signal (NLS) consisting of ForkHead DNA-binding domain and a domain made up of basic 
amino acids.  This NLS is responsible for importing these factors into the nucleus of a cell. 
Inside the nucleus, they bind to certain elements on the DNA and bring about apoptosis of the 
cells. For example, FKHR1 is found to bind to the DNA Response Element known as ForkHead 
Response Element (FHRE) resulting in the activation of Fas ligand gene (a death gene). Akt has 
been found to inhibit these transcription factors.
41
 When survival factors are present, Akt 
phosphorylates 3 sites in FKHR1 – T32, S253 and S315. The phosphorylation of T32, S253 (to a 
major extent) and S315 (to a minor extent) causes FKHR1 to bind to a scaffolding protein 14-3-3 
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in the cytoplasm. The S253 phosphorylation site overlaps with the domain made up of basic 
amino acids. This gives a negative charge to the otherwise positively charged domain. Thus, the 
NLS gets disrupted and no longer transports FKHR1 into the nucleus and gets sequestered in the 
cytoplasm to the scaffolding protein. Hence, the apoptotic genes are not activated. As a result, 
the cell survives (Figure 7). 
1.5.2.2 BH3-only protein BAD (B-cell lymphoma-2 Associated Death promoter) 
BAD is a Bcl-2 Homology domain 3 (BH3)-only protein. In its dephosphorylated state, it binds 
to prosurvival Bcl-2 family members (such as BCL-XL) and inactivates them, leading to 
apoptosis. In the presence of survival factors, AKT phosphorylates S136 on BAD; causing 
binding of 14-3-3 proteins to the complex of BAD and BCL-XL. This helps in the 
phosphorylation of S155 of BAD by kinases. This phosphorylation leads to the dissociation of 
BAD from BCL-XL, thereby preventing apoptosis. 
42,43
 
 
Figure 7.  Regulation of FKHR1 by AKT 
 15 
 
 
1.5.3 Protein synthesis or cell growth regulators  
These include Tuberous Sclerosis Complexes 1/2 (TSC1/2), mTORC1 (mammalian Target Of 
Rapamycin Complex 1), 4E-binding protein-1 (4E-BP1), etc. 
1.5.3.1 mTORC1 and Tuberous Sclerosis Complexes 1/2 (TSC1/2) 
AKT indirectly activates mTORC1 (Figure 8). AKT phosphorylates TSC2 at multiple sites (in 
the TSC1-TSC2 complex).
44
 This prevents TSC1-TSC2 complex from hydrolyzing GTP on 
Rheb to GDP. Thus, Rheb-GTP accumulates in the cell, which activates mTORC1.
45
 mTORC1 
then phosphorylates downstream targets such as 4E-BP1 (4E-Binding Protein 1), resulting in 
translation of mRNA leading to cell survival. mTORC1 also phosphorylates IRS-1 (Insulin 
Receptor Substrate-1) resulting in its degradation. This acts as a negative feedback mechanism of 
AKT signaling pathway. 
46 
 
 
Figure 8. Regulation of mTORC1 by AKT 
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1.6 AKT signaling pathway and cancer 
Alterations of AKT have been implicated in many types of cancers. 
1.6.1 AKT gene over expression and amplification 
Alteration of AKT gene expression was first identified in 1992 in human cancer.
47
 Akt2 was 
found to be amplified and over expressed in ovarian carcinoma cell lines, 12% of primary 
ovarian carcinomas and 3% of breast carcinomas.
48
 When Akt2 is over expressed, it could make 
the cells excessively responsive to normal levels of growth factors, leading to cell proliferation.
49
 
Akt2 has also been found to be over expressed and/or amplified in pancreatic cancer cell lines 
and 10-20% of primary pancreatic carcinomas.
50
 The expression of AKT2 protein has been 
reported to be elevated in 40% of hepatocellular carcinomas.
51
 It has been found to increase 
invasiveness and metastasis in human ovarian and breast cancer cells by up regulating 
integrins.
52
 The amplification of Akt1 and Akt3 are not common in cancers.  
1.6.2 AKT hyper activation 
Activation of AKT has been reported in many types of human cancers (Table 2).
53,54 
Correlation 
between AKT activation and disease advancement/poor prognosis has been reported. AKT1 
kinase activity was found to be increased in 40% of breast and ovarian cancers, >50% of 
prostrate carcinomas.
55
 AKT2 kinase activation was found in 30-40% of pancreatic cancers.
56 
1.6.3 AKT signaling pathway alterations 
The activation of AKT signaling pathway can occur by a variety of mechanisms. Over 
expression of growth factor receptors (wild-type) hyper-sensitize the cells to normal levels of 
growth factors leading to AKT activation.
57
 Constitutive activation of AKT could be caused by 
mutant receptors.
58
 Mutations in PIK3R1 gene (which encodes PI3-kinase) have been detected in 
 17 
 
a few colorectal and ovarian tumors.
59
 Mutations and inactivation of PTEN (a negative regulator 
of AKT) have been reported in endometrial and prostrate cancers.
60
 
Thus, AKT is an appealing target for cancer therapy.  
 
Table 2. Activation of AKT in human cancers 
Tumor type % Tumors with active AKT 
  
Glioma ~ 55 
Thyroid carcinoma 80 - 100 
Breast carcinoma 20 - 55 
Small-lung cell carcinoma ~ 60 
Non-small-cell lung carcinoma 30 - 75 
Gastric carcinoma ~ 80 
Gastrointestinal stromal tumors ~ 30 
Pancreatic carcinoma 30 - 70 
Bile duct carcinoma ~ 85 
Ovarian carcinoma 40 - 70 
Endometrial carcinoma > 35 
Prostrate carcinoma 45 - 55 
Renal cell carcinoma ~ 40 
Anaplastic large-cell lymphoma ~ 100 
Acute myeloid leukemia ~ 70 
Multiple myeloma ~ 90 
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CHAPTER 2 
INHIBITORS OF AKT 
Because of the sequence similarity among the isoforms of AKT, it has been a challenge to 
develop isoform-specific inhibitors. The sites on AKT enzyme against which inhibitors can be 
developed are: ATP binding site, phosphoinositide binding site on the PH domain, substrate 
binding site and allosteric site. Different types of inhibitors developed to date are discussed 
below. 
2.1 ATP-Competitive inhibitors 
ATP is essential for kinase activity. Preventing binding of ATP to AKT is one of the approaches 
to inhibit the enzyme. The ATP binding site is conserved among AKT, PKA and PKC. Many 
inhibitors of PKA, PKC and kinases in other families have been found to inhibit AKT and their 
structures have been optimized to improve selectivity towards AKT. For example, analogs of 
balanol (a non-selective kinase inhibitor) have been developed. (Figure 9) Compound 2-1 has an 
IC50 of 2 nM against PKA and 4 nM against AKT1 in vitro.
61
 The potent PKA inhibitor 2-2 (H-
89) (IC50 0.035 µM against PKA, 2.5 µM against AKT1) has been optimized to give compound 
2-3 (NL-71-101) which has an IC50 9 µM against PKA and 3.7 µM against AKT1 in vitro.
62
 
During a high-throughput screening, Abbott researchers found the bispyridine compound 2-4 to 
be an AKT1 inhibitor (IC50 5 µM).
63
 Based on this scaffold, several 3,5-disubstituted pyridine 
analogs were developed (Figure 10). They were found to be ATP-competitive inhibitors both in 
vitro and in vivo. The most potent inhibitor in this series was compound 2-5 (Ki = 0.16 nM 
against AKT1).
64
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Figure 9. Early ATP-competitive inhibitors 
 
 
 
                                                                                           
     
Figure 10. 3,5-disubstituted pyridine analogs as ATP-competitive AKT inhibitors 
           
In 2008, Glaxo Smith Kline reported lead optimization studies on two compounds (2-6 and 2-7) 
that were identified in a high-throughput screen as AKT inhibitors.
65
 These studies resulted in 
the development of the compound 2-8 (GSK690693) which is an ATP-competitive, AKT kinase 
inhibitor (IC50 2, 13 and 9 nM against AKT1, AKT2 and AKT3 respectively) (Figure 11). It was 
2-1 
PKA IC50 = 2 nM 
AKT1 IC50 = 4 nM 
2-4 
AKT1 IC50 = 5 µM 
2-5 
AKT1 Ki = 0.16 nM 
2-2 (H-89)                     
R = H, X = Br        
PKA IC50 = 0.035 µM 
AKT1 IC50 = 2.5 µM 
 
2-3 (NL-71-101) 
R = Ph, X = H 
PKA IC50 = 9 µM 
AKT1 IC50 = 3.7 µM 
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co-crystallized with the kinase domain of AKT2 (148-481) and the X-ray co-crystal structure 
was reported. (Figure 12) Accordingly, this compound occupies the ATP-binding pocket. The 
interactions observed are the hydrogen bonds between N5 of oxadiazole ring and NH of Ala232 
in the hinge region; NH of piperidine ring and Glu236 carboxylic acid group in the substrate 
binding region. A hydrogen bond network between hydroxyl group of the alkyne, Glu200 
carboxylic acid group and NH of Phe294. This OH group might have displaced the water 
molecule in the enzyme. The intramolecular hydrogen bond between exocyclic NH of the 
oxadiazole ring and N3 of the imidazopyridine ring appears to keep both the rings coplanar.   
                                                               
 
 
 
 
                                                                               
     
 
Figure 11. Oxadiazole containing AKT inhibitors 
2-6 
AKT1 IC50 = 0.120 µM 
2-7 
AKT1 IC50 = 0.355 µM 
2-8 (GSK690693) 
AKT1 IC50 = 2 nM 
AKT2 IC50 = 13 nM 
AKT3 IC50 = 9 nM 
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GSK690693 has been found to inhibit GSK3β phosphorylation in vivo and cause inhibition of 
the tumor xenograft (BT474 - breast carcinoma) growth in mice. It is currently in clinical trials to 
treat solid tumors and hematological malignancies in patients. 
 
 
Figure 12. Model of GSK690693 showing interactions with AKT2 (148-481 residues)
65
 
During a high-throughput screen, Pfizer identified a pyrrolopyrimidine compound 2-9 as an 
AKT1 inhibitor (IC50 210 nM).
66
 Analogs of this compound were synthesized (Figure 13) and 
the best analog 2-10 (IC50 151 nM) was co-crystallized with the kinase domain of AKT1. In this 
structure, two nitrogens of the pyrrolopyrimidine ring are involved in hydrogen bonding 
interactions at the hinge region; two nitrogens of the triazole ring are involved in hydrogen 
bonding with two water molecules and π-stack with Phe161; and there is one intramolecular 
hydrogen bond between the NH of aniline and one nitrogen of the triazole (Figure 14). Thus, 
rigidity can be tolerated here. Based on this, imidazopiperidine analogs were synthesized. The 
compound 2-11 was the most potent one (IC50 42 nM). 2-11 was co-crystallized with the kinase 
domain of AKT1 (Figure 14). The interactions in 2-11 are – two hydrogen bonds between the 
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nitrogens on the imidazole ring and glutamate 234 and aspartate 292 (in contrast to water 
molecules as in compound 2-10) in the region where ribose of ATP binds. There is no π-stacking 
as the Phe 161 is pushed away.  The pyrrolopyrimide ring shows similar interactions as that in 2-
10. Further analogs were prepared and the spiro compound 2-12 was found to be a very potent 
AKT1 inhibitor (IC50 2.4 nM) and to inhibit tumors in vivo. 
 
                                                                                             
 
          
 
 
                                                                                                   
                                   
        
Figure 13. Pyrrolopyrimidine analogs as ATP-competitive AKT inhibitors 
 
2-9 
AKT1 IC50 = 210 nM 
2-10 
AKT1 IC50 = 151 nM 
2-11 
AKT1 IC50 = 42 nM 
2-12 
AKT1 IC50 = 2.4 nM 
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Figure 14. AKT1 kinase domain co-crystals with pyrrolopyrimidine inhibitors 
“Reprinted from Lippa, B.; Pan, G.; Corbett, M.; Li, C.; Kauffmam, G. S.; Pandit, J.; Robinson, 
S.; Wei, L.; Kozina, E.; Marr, E. S.; Borzillo, G.; Knauth, E.; Barbacci-Tobin, E. G.; Vincent, P.; 
Troutman, M.; Baker, D.; Rajamohan, F.; Kakar, S.; Clark, T.; Morris, J. Synthesis and structure 
based optimization of novel Akt inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 3359-3363, 
Copyright 2008, with permission from Elsevier.” 
 
2.2 Drugs that target PH domain  
PI(3,4,5)P3 binds to AKT and subsequently facilitates translocation to the plasma membrane 
resulting in activation of AKT. Blockade of PIP3 binding would thus prevent the translocation 
and activation of AKT. A crystal structure of the PH domain of AKT bound to PI(3,4,5)P3 has 
been reported.
11
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It is found that D3 and D4 phosphate groups of the inositol interact with basic residues (lysine, 
arginine) in the phosphoinositide binding site on the PH domain. These ionic interactions are 
very essential for phosphoinositide binding to AKT (mutations of the basic residues to non-basic 
residues resulted in the decrease/abolition of phosphoinositide binding). The D5 phosphate is not 
much involved in binding to the PH domain as it faces the solvent and interacts with some water 
molecules.  
                              
Figure 15. D-3-deoxy-myo-inositol and PI(3,4,5)P3 
Several phosphoinositide analog inhibitors have been developed. This approach was based on the 
observation that D-3-deoxy-myo-inositols (Figure 15) inhibit the growth of transformed cells.
67
 
These inositols lack the hydroxyl group at the 3
_
position, so they cannot be phosphorylated by 
PI3K. Analogs of phosphatidyl-myo-inositol were made, such as compounds 2-13 (DPI) which 
has IC50 35 µM in HT-29 cells
68
 and 2-14 (DPIEL) that has IC50 2.1 µM in HT-29 cells, which 
is more stable than 2-13 (DPI) inside cells as it is resistant to phospholipases.
69
  
The crystal structure of IP(1,3,4,5)4 with the PH domain of AKT showed that the equatorial 
phosphates at 1,3,4 and the axial OH group at 2 position (oriented inside the binding pocket) of 
inositol ring are involved in hydrogen bonding at the phosphoinositide binding site. By the use of 
molecular modeling of PH domain of AKT, phosphatidylinositol ether lipid analog inhibitors 
have been developed.
70
 Compound 2-15 (PIA5) was found to be very potent (IC50 4.13 µM in 
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H1703 cells) (Figure 16). Based on docking studies, it has been hypothesized that the substituted 
hydroxyl group at position 2 is oriented outside the binding pocket. Hence, in order to maximize 
hydrogen bonding interactions at the other positions, the ring has to be rotated; this results in the 
reorientation of the lipophilic side chains. This could change the conformation of the PH domain 
subsequently leading to the inactivation of AKT. These analogs were found to inhibit the 
phosphorylation of only the targets downstream of AKT. Their ability to cause apoptosis was 
higher in cells that had a higher AKT activity compared to cells with low AKT activity. The 
major problem with these compounds is their poor pharmacokinetics because of their low 
solubility and a tendency to form aggregates. Replacement of the phosphate group by a 
carbonate group diminished their AKT inhibition activity. Dimers of the compounds were also 
found to be inactive. Nevertheless, this binding pocket is not a suitable target for drug 
development as it is shallow.
9
 
                       
 
 
 
 
 
Figure 16. Phosphatidylinositol analog inhibitors of AKT     
2-13 (DPI) 
H-29 cells 
 IC50 = 35 µM 
 
2-14 (DPIEL) 
HT-29 cells 
 IC50 = 35 µM 
 
2-15 (PIA5) 
H1703 cells 
 IC50 = 4.13 µM 
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2.3 Inhibitors that bind at the substrate binding site 
These inhibitors have a greater selectivity compared to the first two classes. They can be further 
classified as -  
2.3.1 Pseudosubstrate peptidic inhibitors 
 A 14-mer peptide called AKTide-2T (2-16) which has the sequence ARKRERTYSFGHHA had 
been identified as an inhibitor of AKT (Ki 12 µM against mouse AKT1) which binds to the 
substrate-binding site by Obata et al in 2000.
71
 Later, in 2004, Luo et al constructed a 20-mer 
peptide (2-17) which was a hybrid between AKTide-2T and 16-24 amino acids of FOXO3 
(VELDPEFEP). Peptide 2-17 is more potent than 2-16 probably due to higher number of 
interactions with AKT. Several analogs were made (Table 3). When the serine at position 17 
was changed to alanine (2-18), the inhibition increased most likely because this peptide binds to 
the substrate-binding site, but can neither be phosphorylated nor can detach from the site. The 
inhibition decreased when Ser17 was changed to Aspartate (2-19; most likely because the 
carboxy group of Asp occupies the site of phosphate of ATP). Peptides 2-20 and 2-21 had 
Alanine and Aspartate at position 15 respectively. Except peptide 2-17 (which inhibited SGK 
also), all other compounds were found to selectively inhibit AKT. It was found that a peptide 
must have at least 17 amino acids in order to inhibit AKT effectively (Table 4). These 
compounds inhibited GSK3 phosphorylation but not growth (the peptides might be not be stable 
over time) in HeLa cells. The peptides were found to be highly selective towards AKT (over 
other kinases).
72
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Table 3.  Pseudosubstrate peptidic inhibitors of AKT1 
Number Peptide sequence AKT1 Ki (µM) 
2-16 (AKTide-2T)         ARKRERTYSFGHHA 12 
2-17 VELDPEFEPRARERTYSFGH 1.11 
2-18 VELDPEFEPRARERTYAFGH 0.11 
2-19 VELDPEFEPRARERTYDFGH 10.6 
2-20 VELDPEFEPRARERAYAFGH 0.095 
2-21 VELDPEFEPRARERDYAFGH >16 
 
                                           
Table 4. Minimum number of amino acids required for peptide inhibitors 
Number of amino acids Peptide sequence AKT1 Ki (µM) 
8             Ac-ERTYAFGH >100 
11          Ac-RARERTYAFGH 15.86 
14          FEPRARERTYAFGH 1.97 
14       Ac-FEPRARERTYAFGH 1.44 
17    Ac-DPEFEPRARERTYAFGH 0.26 
20    VELDPEFEPRARERTYAFGH 0.18 
20 Ac-VELDPEFEPRARERTYAFGH 0.098 
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2.3.2 Peptidic substrate-mimetic inhibitors  
In 1996, Alessi et al had identified the minimum consensus sequence of a substrate to be 
phosphorylated by AKT as RXRYYS/TZ (X-any amino acid, Y-small residues except glycine, 
Z-bulky hydrophobic residue). While testing the phosphorylation of various peptide sequences 
by AKT1, they found two peptide sequences that had very low Km values and high specificity for 
AKT1 compared to MAPKAP kinase-1 and p70 S6 kinase : RPRTSSF (Km 5 µM) and 
GRPRTSSF (Km 8 µM). 
In 2002, the X-ray crystal structure of activated AKT in complex with GSK3β (10 residue 
sequence) and an ATP analog was published.
12
 This showed that the sequence GRPRTTSFAE is 
bound to the substrate binding site via many interactions (Figure 17). This sequence is similar to 
the one reported by Alessi et al in 1996 (GRPRTSSF). In 2007, Hamilton & coworkers utilized 
the sequence GRPRTTSF (8 residues) to make about 35 analogs. It was found that the three 
residues (GRP) at N-terminal hydrophilic region were not necessary. They could be replaced by 
an acetyl group. The arginine at the 4
th
 position was very essential. The Threonine residues at 
positions 5 and 6 were not necessary; they could be replaced by p-amino benzoic acid. The 
Serine at position 7 could be changed to a Valine. Phenylalanine at position 8 was necessary to 
make hydrophobic interactions. A hydrophobic ring could be added to the C-terminal 
phenylalanine in order to increase the binding interactions at the C-terminal region. Another 
hydrophobic group could be added to the N-terminus. These modifications led to the 
development of a potent AKT1 inhibitor 2-22 (IC50 14 µM) (Figure 17). This shows that only 3 
amino acid residues out of 8 are necessary to inhibit AKT and they can be linked by non-peptidic 
groups to improve the hydrophobicity of these compounds which is essential for cell 
permeability.
73
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GSK3β (10 residue sequence) interacting with AKT1 residues 
 
 
                                             
            
Figure 17. Peptide substrate-mimetic inhibitors 
Non-peptide substrate-mimetic inhibitors:  By using docking studies, improvements were made 
on the peptidic substrate-mimetics to give the first non-peptide substrate-mimetic inhibitors 2-23, 
2-24 of AKT (Figure 18). These compounds are more hydrophobic and rigid compared to the 
peptidic compounds.
74
  
2-22 
AKT1 IC50 = 14 µM 
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Figure 18. Non-peptide substrate-mimetic inhibitors 
 
2.4 Allosteric inhibitors 
These inhibitors not only specific for AKT over other kinases, but are also AKT isoenzyme 
specific. Barnett et al had identified compound 2-25 (IC50 4.6 µM against AKT1 and >250 µM 
against AKT2, AKT3, SGK) as a selective AKT1 inhibitor (Figure 19). Based on the 
observation that 2-25 was active only against AKT1 containing a PH domain and showed non-
competitive inhibition of AKT1 with respect to ATP and peptide substrate; a model for the 
allosteric inhibition of AKT was proposed.
75
 According to this model (Figure 20), these types of 
inhibitors bind to a site which is formed only when PH domain is present. This site could be 
formed due to the conformational changes resulting from interaction of PH domain and kinase 
domain or it could be present at the interface of both the domains. When bound to this site, the 
2-23 
R = CH(CH3)2 
AKT1 IC50 = 17 µM 
 
2-24 
R = CN 
AKT1 IC50 = 12 µM 
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inhibitor locks up AKT in a “closed” conformation and does not allow it to interact with PDK1, 
thereby preventing its phosphorylation and subsequent activation.  
                               
 
 
 
Figure 19. Early isoform-specific allosteric AKT inhibitors 
 
Figure 20.
76
 Model for the allosteric inhibition of AKT 
2-25 
AKT1 IC50 = 4.6 µM 
AKT2, AKT3 IC50 > 250 µM 
 
2-26 
AKT1 IC50 = 3400 nM 
AKT2 IC50 = 23,000 nM 
AKT3 IC50 >50,000 nM 
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In 2005, Merck reported a series of isoenzyme-specific allosteric AKT inhibitors which were PH 
domain dependent.77 During a high-throughput screen targeted at identifying AKT inhibitors, 
they identified the compound 2-26 (Figure 19) to be specific to AKT over other kinases and also 
specific to AKT1 (IC50 s 3400 nM; 23,000 nM and >50,000 nM against AKT1; AKT2 and AKT3 
respectively). This compound was inactive in Akt mutants lacking the PH domain. Several 
analogs of 2-26 were made wherein the 2,3-diphenylquinoxaline scaffold was retained while 
changing the amino group. This resulted in a compound 2-27 (IC50 290 nM against AKT1, 2090 
nM against AKT2 and >50,000 nM against AKT3 & other kinases) which was more potent than 
2-26. But, this compound had poor solubility and no cellular activity.  
Further analoging was done retaining the piperidinyl benzimidazolone scaffold (Figure 21). This 
resulted in AKT1 specific inhibitor 2-28 (IC50 s 760 nM; 24,000 nM and >50,000 nM against 
AKT1; AKT2 and AKT3 respectively) and AKT2 specific inhibitor 2-29 (IC50 s >20,000 nM; 
325 nM and >20,000 nM against AKT1; AKT2 and AKT3 respectively). It was observed that in 
order to achieve maximum apoptotic response, both AKT1 and AKT2 had to be inhibited 
(caspase-3 assay was performed on human ovarian carcinoma cells A2780 using 1:1 mixture of 
2-28 and 2-29). This led to the development of dual AKT1/AKT2 inhibitor 2-30 (IC50 s 58 nM; 
210 nM and 2,119 nM against AKT1; AKT2 and AKT3 respectively) which was potent and 
moderately cell-permeable. In cell-based assay, the IC50 values of 2-30 were 305 nM; 2086 nM 
and >25,000 nM against AKT1; AKT2 and AKT3 respectively. In vivo studies were done in 
mice using 2-30, it was found to inhibit AKT1 and AKT2 but not AKT3 phosphorylation in 
lungs. The position of the allosteric binding site is not yet known. Merck has not published a 
crystal structure yet. 
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Figure 21. Piperidinyl benzimidazolone analogs as allosteric AKT inhibitors 
2-27 
AKT1 IC50 = 290 nM 
AKT2 IC50 = 2090 nM 
AKT3 IC50 >50,000 nM 
 
2-28 
AKT1 IC50 = 760 nM 
AKT2 IC50 = 24,000 nM 
AKT3 IC50 >50,000 nM 
 
2-29 
AKT1 IC50 > 20,000 nM 
AKT2 IC50 = 325 nM 
AKT3 IC50 > 20,000 nM 
 
 
Biochemical 
AKT1 IC50 = 58 nM 
AKT2 IC50 = 210 nM 
AKT3 IC50 > 2119 nM 
 
Cellular 
AKT1 IC50 = 305 nM 
AKT2 IC50 = 2086 nM 
AKT3 IC50 > 25,000 nM 
 
2-30 
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Using Microwave Assisted Organic Synthesis (MAOS), Diversity-Oriented Synthesis (DOS) 
was carried out to make compounds having the canthine alkaloid scaffold (Figure 22).
78
 This 
resulted in the development of two unnatural canthine alkaloids 2-31 (IC50 s 1.3 µM; 1.6 µM and 
>50 µM against AKT1; AKT2 and AKT3 respectively) and 2-32 (IC50 s 1.5 µM; 2.3 µM and >50 
µM) against AKT1; AKT2 and AKT3 respectively). These compounds were found to be dual 
AKT1/AKT2 selective allosteric inhibitors (Figure 23). They were active only against AKT 
having a PH domain and showed non-competitive inhibition towards AKT with respect to ATP. 
 
Figure 22. Canthine alkaloid scaffold 
                           
 
 
 
Figure 23. Unnatural canthine alkaloids 
2-31 
AKT1 IC50 = 1.3 µM 
AKT2 IC50 = 1.6 µM 
AKT3 IC50 > 50 µM 
 
 
2-32 
AKT1 IC50 = 1.5 µM 
AKT2 IC50 = 2.3 µM 
AKT3 IC50 > 50 µM 
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In order to improve the aqueous solubility and cell permeability, further analoging was done on 
2-30. This gave rise to compound 2-33 [IC50 s 138 nM; 212 nM; 7,200 nM (biochemical assay) 
and 253 nM; 276 nM; >10,000 nM (cellular assay) against AKT1; AKT2; AKT3 respectively] 
which was a potent allosteric inhibitor (Figure 24), inhibited phosphorylation in vivo (mice), but 
caused some behavioral effects.
79
 
 
 
 
 
                         
                       
Figure 24. Allosteric AKT inhibitor 2-33 
                            
Attempts to improve both pharmacokinetics and tolerability in vivo resulted in the synthesis of 
several naphthyridines and naphthyridonones (Figure 25).
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Naphthyridine 2-34 had IC50 s of 44 nM; 280 nM (biochemical assay) and 149 nM; 995 nM 
(cellular assay) against AKT1 and AKT2 respectively. The naphthyridonone 2-35 had almost 
comparable activity both in biochemical and cellular assays [IC50 s 3.5 nM; 42 nM (biochemical 
assay) and 16 nM; 266 nM (cellular assay) against AKT1; AKT2 respectively]. In vivo studies 
were performed on mice using 2-35. It was well tolerated. In tumor xenograft study (A2780), it 
Biochemical 
AKT1 IC50 = 138 nM 
AKT2 IC50 = 212 nM 
AKT3 IC50 = 7200 nM 
 
Cellular 
AKT1 IC50 = 253nM 
AKT2 IC50 = 276 nM 
AKT3 IC50 > 10,000 nM 
 
 
2-33 
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showed 95% and 54% inhibition against AKT1 and AKT2 respectively.  A class of 
pyridopyrimidines were developed such as 2-36 [IC50 s 6 nM; 94 nM (biochemical assay) and 
20.3 nM; 899 nM (cellular assay) against AKT1; AKT2 respectively].
81
  
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Naphthyridine and naphthyridonones analogs 
The major problem with some of the compounds discussed above is the off-target binding to a 
potassium channel Ikr hERG (human Ether-a-go-go-Related Gene), which produces cardiac 
Biochemical 
AKT1 IC50 = 44 nM 
AKT2 IC50 = 280 nM 
 
Cellular 
AKT1 IC50 = 149 nM 
AKT2 IC50 = 995 nM 
 
 
Biochemical 
AKT1 IC50 = 3.5 nM 
AKT2 IC50 = 42 nM 
 
Cellular 
AKT1 IC50 = 16 nM 
AKT2 IC50 = 266 nM 
 
 
2-34 
2-35 
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toxicity. In order to reduce this toxicity while maintaining potency towards AKT1 and AKT2, 
different analogs were made. As shown below, many heteroatoms were added to the ring  
 
 
 
 
 
 
 
 
Figure 26. Pyridopyrimidine analogs 
2-36 
 
Biochemical 
AKT1 IC50 = 6 nM 
AKT2 IC50 = 94 nM 
 
Cellular 
AKT1 IC50 = 20.3 nM 
AKT2 IC50 = 899 nM 
 
 
2-37 
 
Biochemical 
AKT1 IC50 = 13 nM 
AKT2 IC50 = 48 nM 
hERG IC50 > 10,000 nM 
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attached to the triazole (this reduced the lipophilicity and probably the π-interactions at hERG 
binding site reducing the off-target issues) and substituents which increased the hydrophilicity at 
the piperazine ring were used (to improve potency). This resulted in compound 2-37 [IC50 s 13 
nM; 48 nM and >10,000 nM (biochemical assay) AKT1; AKT2 and hERG respectively] (Figure 
26).
82
 
Recently, compounds containing [1,2,4]triazolo[3,4-f][1,6]naphthyridines have been reported.
83
 
Compound 2-38 [IC50 s 4 nM, 10 nM (biochemical assay); 5 nM, 41 nM (cellular assay) against 
AKT1, AKT2 respectively] had good potency and no appreciable hERG binding (Figure 27). In 
vivo studies were done in mice. At 1.8 µM blood concentration, it was found to inhibit AKT1 
phosphorylation by 92% and AKT2 phosphorylation by 41% in mouse lung and was well 
tolerated. 
 
 
      
 
Figure 27. [1,2,4]triazolo[3,4-f][1,6]naphthyridine analog 
                             
 
 
 
2-38 
 Biochemical 
AKT1 IC50 = 4 nM 
AKT2 IC50 = 10 nM 
 
 
Cellular 
AKT1 IC50 = 5 nM 
AKT2 IC50 = 41 nM 
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Clinical trials 
Merck’s compound MK-2206 (2-39) is a potent, allosteric, oral AKT inhibitor (Figure 28). The 
first clinical trials were done on 33 patients with advanced solid tumors (April 2008 - November 
2009). It was well tolerated, caused minor adverse effects such as rash and was found to cause 
tumor shrinkage.
84
  
 
 
                       
Figure 28. Oral AKT inhibitor MK-2206 
 
 
 
 
 
 
 
 
 
 
2-39 (MK-2206) 
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CHAPTER 3 
PYRANONAPHTHOQUINONE LACTONES AS AKT INHIBITORS 
3.1 Discovery of PNQ lactones as AKT Inhibitors 
In 2007, during a high-throughput screen to identify inhibitors of activated AKT1, Toral-Barza et 
al discovered the pyranonaphthoquinone lactones lactoquinomycin (IC50 0.149 µM against 
commercially prepared AKT1) (3-1) and frenolicin B (IC50 0.313 µM against commercially 
prepared AKT1) (3-2) to be potent and selective inhibitors of AKT (Figure 29).
85 
Lactoquinomycin was not found to inhibit PKA (IC50 >200 µM). It weakly inhibited PKCα 
(~16% inhibition at 1 µM), HER2 (IC50 2.42 µM), IKKβ (IC50 3.9 µM) and did not inhibit 
closely related tyrosine and serine/threonine kinases (Figure 30). It was also tested against 45 
different kinases at 1µM concentration (Invitrogen SelectScreen profiling), and was found to 
inhibit only AKT1 (92%) and AKT2 (99%) (Table 5). 
 
                                     
 
 
Figure 29. PNQ lactones – lactoquinomycin and frenolicin B 
 
3-1 (Lactoquinomycin) 
AKT1 IC50 = 0.149 µM 
3-2 (Frenolicin B) 
AKT1 IC50 = 0.313 µM 
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Figure 30. Lactoquinomycin IC50 values against 14 different kinases 
 
3.2 Mechanism of inhibition 
 The inhibition of AKT1 by PNQ lactones was found to be non-competitive with respect to ATP. 
It did not require the presence of PH domain (as opposed to the other allosteric AKT inhibitors). 
The mechanism is thought to be an irreversible interaction between cysteines 296 and/or 310 
present in the activation loop (T-loop) of AKT1 and the inhibitor.
85
 The conformation of the T-
loop region of the AKT family might be distinct from other AGC family members. Once 
lactoquinomycin binds to the T-loop cysteines, it could either directly inhibit the binding of 
substrate to AKT or cause a conformational change which inactivates AKT. 
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Table 5. Lactoquinomycin inhibition values against 45 kinases 
Kinase tested % Inhibition 
(1 µM)  
Kinase tested 
 
% Inhibition  
(1 µM) 
ABL1 0 MAP2K1 0 
AKT1 92 MAP4K5 34 
AKT2 99 MAPK1 6 
BTK 1 MAPK14 49 
CDK1 2 MAPK3 7 
CDK2 0 MET 14 
CHEK1 10 NEK2 0 
CSF1R 6 NTRK1 14 
CSK 0 PDGFRA 15 
EGFR 26 PDGFRB 32 
EPHA1 8 PDK1 0 
ERBB4 (HER4) 5 PLK1 0 
FGFR1 38 PRKACA 0 
FLT1 (VEGFR1) 29 PRKCA 16 
FLT3 4 PRKCQ 22 
FYN 17 PTK2 12 
IGF1R 2 ROCK1 1 
IKBKB 41 RPS6KB1 16 
INSR 1 SGK 20 
KDR 21 SRC 0 
LCK 0 STK6 17 
LYN A 3 SYK 2 
  YES1 14 
 
                                          
They have proposed the mechanism of action to be a bioreductive alkylation of the enzyme 
(Figure 31). AKT2 has four cysteine residues – C226, C297, C311 and C345. C226 and C345 
are thought to be inaccessible while C297 and C311 are accessible and can covalently interact 
with the PNQ lactones. According to the above proposed mechanism, the quinone gets reduced 
in vivo and forms a quinone methide. This reacts with nucleophilic groups (like thiols) on the 
proteins. This mechanism is supported by the observation that C311 (in phosphorylated AKT2) 
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and both C297 and C311 (in unphosphorylated AKT2) formed a monoadduct with compound 3-
4 (Figure 32). No disulfide formation was observed between C297 and C311. Hence, PNQ 
lactones are the first known inhibitors which act via a novel bioreductive alkylation mechanism 
of the T-loop cysteines in AKT. 
 
Figure 31. Proposed mechanism for the bioreductive alkylation by PNQ lactones
86 
 
 
Figure 32. Thienyl compound 3-4 
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3.2.1 In vitro experiments 
To confirm the mechanism of action, mutants of C296 and C310 were prepared. In the single T-
loop cysteine mutants of AKT1, C296A (IC50 30.4 µM) and C310A (IC50 38.5 µM), the 
inhibition by lactoquinomycin was reduced to a great extent and was completely lost in the 
double mutant C296A/C310A (IC50 > 40 µM) compared to wild-type AKT1 (IC50 0.36 µM) 
obtained by expression in HEK293 cells. Whereas, Staurosporine (an ATP-competitive inhibitor) 
inhibited the three mutants and the wild-type AKT1 equally. This proved that the PNQ lactones 
did not bind to the ATP-binding site, but bind to the T-loop cysteines.  
3.2.2 Effect on the downstream targets of AKT in tumor cells 
Lactoquinomycin inhibited the phosphorylation of GSK3 in PTEN-negative U87MG cells 
(PTEN is a negative regulator of AKT). It also inhibited the phosphorylation of FKHRL1 
induced by IGF-1 in Rat1 cells. It was observed that the phosphorylation of AKT at S473 and 
T308 was minimally affected by lactoquinomycin (suggesting that upstream kinases PDK1 and 
mTORC2 were not inhibited). In DU-AKT cells, lactoquinomycin inhibited the phosphorylation 
of S6K and 4EBP1 (substrates of mTORC1), suggesting that it inhibited mTORC1. 
 
In 2009, Salaski et al determined the Structure-Activity Relationship (SAR) of the 
pyranonaphthoquinone lactones required to inhibit AKT:
86
 the structure 3-3 (Figure 33) is the 
minimum scaffold required; amino sugar at position 8 and hydroxyl group at position 7 are not 
required; closed lactone ring is more potent compared to lactone formed in situ; bulky groups are 
tolerated at position 5; disubstitution at position 5 decreases the potency and the absolute 
configuration of the PNQ lactone has no effect on its inhibitory activity (Table 6).  
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3-3 
Figure 33. PNQ lactone scaffold 
Table 6. SAR of PNQ lactones 
R Stereochemistry AKT IC50 (µM) 
 
H (+) 0.044 
2-thienyl (+)-anti 0.057 
CH2OBn (±)-anti 0.072 
4-hydroxyphenyl (±)-syn 0.08 
3-thienyl (-)-anti 0.099 
3-thienyl (+)-anti 0.122 
methyl (+)-anti 0.15 
n-propyl (±)-anti 0.163 
(CH2)4 (±) 0.295 
3-hydroxyphenyl (±)-syn 0.35 
n-propyl (±)-syn 0.383 
4-aminophenyl (±)-syn 0.85 
gem-dimethyl (±) 1.44 
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CHAPTER 4 
SYNTHESIS AND EVALUATION OF 7-DEOXYKALAFUNGIN AND ITS 
DECONSTRUCTION ANALOGS 
4.1 Rationale 
Wyeth researchers had reported the SAR of PNQ lactones necessary for inhibiting AKT in 
2009.
86 
We sought to further investigate the SAR in order to determine what structural features 
are required for AKT1 inhibition and what structural features are required for selectivity over the 
closely related kinase PKA. To achieve this, the synthesis of 7-deoxykalafungin and its 
deconstruction analogs was carried out. 
 
4.2 Literature review 
Several schemes for the syntheses of PNQ lactones have been reported to date, a few of which 
are highlighted below. 
4.2.1 Enantiospecific total syntheses 
In 1985, the first enatiospecific total syntheses of kalafungin and its enantiomers nanaomycin D 
was reported by Tatsuka et al.87 Starting from L-rhamnose, compound 4-3 was synthesized in 
five steps. This was then condensed (Hauser annulation reaction) with compound 4-4 to give the 
pyranonaphthoquinone 4-5.  This was converted to the common “optically active intermediate” 
4-8 in three steps (Figure 34).  
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Using “enantiodivergent” strategy, 4-8 was converted to 4-9 and 4-10 in a Wittig reaction using 
ethoxycarbonylmethylenetriphenylph-osphorane. 4-9 and 4-10 were converted to kalafungin (4-
11) and nanaomycin D (4-12) respectively (Figure 35). 
 
 
 
Figure 34. Synthesis of optically active intermediate 4-8 
 
Figure 35. The first enantiodivergent total syntheses of kalafungin (4-11), nanaomycin D (4-12) 
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4.2.2 Regioselective Diels-Alder reactions 
In 1995, Kraus et al reported the total syntheses of frenolicin B (4-17) and racemic kalafungin 
using regioselective Diels-Alder reactions (Figure 36).
88
 Metalation on 4-13 followed by 
reaction with acrolein afforded 4-14. Palladium catalyzed reaction in the presence of carbon 
monoxide yielded the tricyclic compound 4-15 which on treatment with silver oxide gave 4-16. 
Regioselective Diels-Alder reaction on 4-16 followed by Jones oxidation afforded frenolicin B 
(4-17). 
 
 
Figure 36. Total synthesis of frenolicin B (4-17) by regioselective Diels-Alder reaction 
 
4.2.3 Furofuran annulation/Oxidative rearrangement 
In 2000, Brimble reported the syntheses of kalafungin and other PNQ lactones using furofuran 
annulation/oxidative rearrangement strategy (Figure 37).
89
 Starting from commercially available 
1,5-dihydroxynaphthalene, 4-25 was synthesized in 6 steps. This underwent furofuran annulation 
with 4-26 to form the tetracyclic compound 4-27. 4-27 underwent oxidative rearrangement in the 
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presence of CAN to give 4-28. The cis-ether was reduced to give 4-29, which was deprotected 
and epimerized to form kalafungin (4-11). 
 
 
Figure 37. Synthesis of kalafungin (4-11) using furofuran annulation/oxidative rearrangement 
 
4.2.4 Asymmetric Dihydroxylation, Oxa-Pictet Spengler cyclization in the synthesis of 
Kalafungin and Nanaomycin 
In 2005, Fernandes and Bruckner reported the synthesis of kalafungin and its enantiomer 
nanaomycin by Asymmetric Dihydroxylation and Oxa-Pictet Spengler cyclization reactions as 
the key steps (Figure 38).
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 Starting from 1,5-dihydroxynaphthalene (4-18), the compound 4-30 
was synthesized in five steps. 4-30 was converted to 4-31 utilising Palladium-catalyzed reaction. 
Sharpless Asymmetric Dihydroxylation (SAD) was carried out on 4-31 using (DHQD)2PHAL as 
the ligand to give 4-32. This underwent Oxa-Pictet Spengler cyclization to form the 
pyranonaphthoquinone lactone 4-33. Upon CAN oxidation, methoxy deprotection and 
epimerization, kalafungin (4-11) was formed. nanaomycin D was synthesized using the same 
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synthetic scheme, the only difference being the use of (DHQ)2PHAL as the ligand in the SAD 
reaction. 
 
 
Figure 38. Kalafungin synthesis using SAD, Oxa-Pictet Spengler reactions 
 
4.2.5 Michael-Dieckmann approach in the total synthesis of Kalafungin 
In 2007, Donner reported the total synthesis of kalafungin using a tandem Michael-Dieckmann 
approach as shown below (Figure 39).
91
 Starting from (S)-aspartic acid, compound 4-35 was 
formed in 5 steps. 4-34 reacted with 4-35 in a Michael-Dieckmann reaction to give the 
naphthopyranone 4-36. This was subsequently converted to kalafungin 4-11. 
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Figure 39. Total synthesis of kalafungin using Michael-Dieckmann reaction 
 
 
4.3 Preparation of 7-deoxykalafungin and its deconstruction analogs  
4.3.1 Synthesis of 7-deoxykalafungin (4-46) 
 We chose to synthesize 7-deoxykalafungin because of the ease of its synthetic accessibility and 
AKT (IC50 0.044 µM)
86 
inhibition data reported in the literature. The synthetic scheme (Figure 
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40) was chosen as it was a synthetically convenient route, had good literature precedent
92
 and 
could be easily branched to make analogs. 
Synthesis of 4-42 
Starting from commercially available 4-41, bromination was carried out using N-
bromosuccinimide in dichloromethane to give 4-42 in 96% yield. 
Synthesis of 4-43 
Heck-coupling between 4-42 and iso-butyl vinyl acetate afforded 4-43 in 81% yield. This 
reaction required strict anhydrous and air-free conditions. The solvent toluene was dried over 
molecular sieves and degassed thoroughly using argon, prior to use. The catalyst used was 
bis(tri-tert-butylphosphine) palladium (0) which is highly air and moisture-sensitive. Using 2 
mol% of the catalyst (as reported in the literature)
92
 resulted in only ~10% conversion to the 
product. Optimization of this reaction (with iso-butylvinylacetate as the constant coupling 
partner) was previously carried out on very similar substrates (model substrates 4-47 and 4-49) 
(Figure 41) using several other catalysts such as palladium acetate (II), palladium on carbon, etc 
(Table 7). Unfortunately, none of these catalysts worked. Finally, when the catalyst bis(tri-tert-
butylphosphine) palladium (0) was increased from 2 mol% to 6 mol%, it resulted in ~70% 
conversion of the model substrate 4-47. The same conditions were applied to 4-42. Use of 6 
mol% of the catalyst resulted in 81% of the product 4-43. Thus, bis(tri-tert-butylphosphine) 
palladium (0) is a highly efficient catalyst for electron-rich aryl compounds. 
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Figure 40. Synthesis of 7-deoxykalafungin 
 
Figure 41. Optimization of Heck-coupling reaction on model substrates 
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Table 7. Optimization of Heck-coupling reaction using iso-butylvinylacetate 
Substrate 
Catalyst (w/wo 
ligand) 
Base 
# Eq. of 
catalyst 
Solvent 
Temp. 
(
o
C) 
Yield (%) 
4-48/4-50 
4-47 Pd(t-Bu3P)2 Cy2NMe 0.02 Toluene 111 <10 
4-47 Pd(t-Bu3P)2 Cy2NMe 0.02 DMF 154 0 
4-47 Pd(t-Bu3P)2 Cy2NMe 0.02 DMF 120 0 
4-47 
Pd(OAc)2 + 
P(o-tolyl)3 
NaOAc 0.04 Toluene 111 0 
4-47 Pd(t-Bu3P)2 Cy2NMe 0.06 Toluene 111 70 
4-49 Pd(t-Bu3P)2 Cy2NMe 0.02 DMF 154 0 
4-49 Pd(t-Bu3P)2 (i-Pr)2NEt 0.02 Toluene 111 0 
4-49 Pd(OAc)2 + PPh3 Cy2NMe 0.02 DMF 95 0 
4-49 Pd(dba)2 + PPh3 Cy2NMe 0.02 DMF 95 0 
4-49 Pd/C (10%) Cy2NMe 0.10 Toluene 111 0 
 
 
Sharpless Asymmetric Dihydroxylation (SAD) on 4-43 
Sharpless Asymmetric Dihydroxylation was carried out on 4-43 to give 4-44. Use of 
commercially available AD-mixβ [(DHQD)2PHAL - 0.0016 mole, potassium carbonate powder - 
0.4988 mole, potassium ferricyanide - 0.4988 mole, potassium osmate dihydrate - 0.0007 mole] 
gave non-reproducible results. Hence, the reagents were added separately. The yield of this 
reaction was low (~50%). Sodium bicarbonate was added to buffer the reaction. This slightly 
improved the yield (53%). The reaction resulted in a mixture of lactonized and unlactonized 
products. In order to force the lactonization to proceed to completion, the mixture was treated 
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with sodium hydroxide to hydrolyze any isobutyl ester present in the dihydroxylated product to 
an acid. It was then acidified with hydrochloric acid and lactonized using p-toluene sulfonic acid 
(p-TsOH) as the catalyst. Unfortunately, the yield of this reaction could not be improved. Even 
after trying different conditions of temperature and time, around 35% of the starting material 
remained unreacted and the rest was converted to by-products which could not be characterized. 
The major advantage of this reaction is that the product formed is a single isomer [(R, R) in this 
case due to the ligand (DHQD)2PHAL used]. 
Synthesis of 4-45 
Oxa-Pictet Spengler cyclization was carried out on 4-44 to give 4-45 in 93% yield. Use of 
acetaldehyde in dichloromethane in the presence of the Lewis acid - boron trifluoride diethyl 
etherate yielded exclusively the trans product 4-45 (trans relationship between positions 5 and 
3a; 5 and 11a). 
Synthesis of 4-46 
4-45 was oxidized using ammonium cerium (IV) nitrate in water and acetonitrile mixture (1:1) to 
4-46 in 72% yield. The stereochemistry of 4-46 was the same as that of 4-45. 
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4.3.2 Deconstruction scheme for 7-deoxykalafungin  
4-46 gets reduced in vivo to the quinone methide (Figure 42). This quinone methide is a very 
reactive Michael acceptor and it alkylates nucleophiles such as thiol groups in the proteins. In a 
similar manner to 4-46, 4-61 would get reduced in vivo to 4-61B.  
To determine if the pyran ring is essential for activity, the compound 4-61 was synthesized. The 
naphthoquinone and the lactone rings were retained in 4-61, which can still form a quinone 
methide. To find out if the lactone ring is essential for the activity, the compound 4-60 was 
synthesized, which does not have a lactone ring and cannot form a quinone methide.  
In order to find out if just the Michael acceptor is sufficient to inhibit AKT1, 4-61C was to be 
synthesized (the allylic oxidation reaction on 4-56 to form 4-61C was unsuccessful). To know if 
the hydroxyl group in 4-61C is essential, the compounds 4-59 (acid) and 4-56 (ester) were made, 
which lack the hydroxyl group, but retain the Michael acceptor. 
To see if the length of the chain attached to phenyl ring had any influence on the activity of the 
compounds, 4-54 was made, which retained the Michael acceptor. 4-54 was further 
deconstructed to form 4-52 - the simplest deconstruction analog. The scheme is shown in Figure 
42. 
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Figure 42. Deconstruction scheme for 7-deoxykalafungin 
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4.3.3 Synthesis of the deconstruction analogs of 7-deoxykalafungin: (figure 42) 
Synthesis of 4-51 
Benzoic acid was treated with N,O-Dimethylhydroxylamine hydrochloride in the presence of the 
coupling reagent EDC•HCl and base N-methyl morpholine to give the Weinreb amide 4-51 in 
84% yield.  
Synthesis of 4-52 
Grignard reaction was carried out on 4-51 using vinylmagnesium bromide in dry diethyl ether. 
When THF was used as the solvent, the compound formed degraded during quenching of the 
reaction mixture. This reaction required strict anhydrous conditions and was performed under 
argon. The vinylmagnesium bromide solution had to be added very slowly over a period of 30 
min. The product 4-52 was formed in 55% yield (Figure 43). 
 
 
Figure 43. Synthesis of 4-51 and 4-52 
Synthesis of 4-54  
The allyl methyl ether (3-metoxyprop-1-ene) was treated with 4-52 in the presence of the cross-
metathesis (CM) catalyst (4-53) (Figure 44) in dichloromethane to afford 4-54 in 30% yield 
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(Figure 45). This reaction resulted in exclusively the trans compound. The yield was low due to 
the self-metathesis of the aliphatic partner. The phenyl vinyl ketone (4-52) underwent self-
metathesis to a very low extent. 
 
Figure 44. Cross Metathesis catalyst 4-53 (CAS number 253688-91-4) 
 
 
Figure 45. Synthesis of 4-54 
Synthesis of 4-55 
Pent-4-enoic acid was treated with methyl iodide in the presence of potassium carbonate in 
acetone to afford 4-55 in 57% yield (Figure 46).  
Synthesis of 4-56  
Cross-metathesis between 4-55 and 4-52 was carried out in dichloromethane using the cross-
metathesis catalyst to afford 4-56 in 41% yield (Figure 46). This reaction resulted in exclusively 
the trans compound. The yield was low due to the self-metathesis of the aliphatic partner. The 
phenyl vinyl ketone (4-52) underwent self-metathesis to a very low extent.  
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Figure 46. Synthesis of 4-55 and 4-56 
 
Synthesis of 4-57 
Pent-4-enoic acid was protected as the t-butyl ester using t-butanol in the presence of the 
coupling reagent DCC and the catalyst 4-dimethyl amino pyridine (Figure 47). The product 4-57 
was formed in 40% yield. A by-product was formed in ~40% yield which could not be 
characterized. 
Synthesis of 4-58 
Cross-metathesis between 4-57 and 4-52 was carried out in dichloromethane using the cross-
metathesis catalyst to afford 4-58 in 46% yield. This reaction resulted in exclusively the trans 
compound. The yield was low due to the self-metathesis of the aliphatic partner. The phenyl 
vinyl ketone (4-52) underwent self-metathesis to a very low extent. 
Synthesis of 4-59 
The t-butyl ester of 4-58 was deprotected to give the acid 4-59 in 36% yield (Figure 47). 
Trifluoro acetic acid was used for the deprotection in the presence of the cation scavenger 
triethylsilane. Based on mass spectrum, 4-59 was found to exist mainly as dimers and trimers. 
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The yield was low due to the formation of by-products which could not be characterized by 
NMR spectra. Probably, lactone formation could have taken place as a result of closure of the 
acid group.  
 
Figure 47. Synthesis of 4-57, 4-58 and 4-59 
Synthesis of 4-60 
1,4-dimethoxynaphthalene was oxidized using ammonium cerium (IV) nitrate in water and 
acetonitrile mixture (1:1) to 4-60 in 81% yield (Figure 48).  
 
 
Figure 48. Synthesis of 4-60 
Synthesis of 4-61 
4-44 was oxidized using ammonium cerium (IV) nitrate in water and acetonitrile mixture (1:1) to 
4-61 in 65% yield (Figure 49). The stereochemistry of 4-61 was the same as that of 4-44.  
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Figure 49. Synthesis of 4-61 
 
4.4 Evaluation of the kinase inhibition of the compounds  
We chose the Z′-LYTE® kinase assay system to evaluate these compounds. 
4.4.1 Z′-LYTE® assay principle 
The Z′-LYTE® biochemical assay (Invitrogen, NY, USA) is used to measure the kinase (AKT1, 
PKA, etc.) inhibition. In a kinase (primary) reaction, the kinase transfers a phosphate group from 
ATP to a serine/threonine/tyrosine residue present in the FRET peptide. The FRET peptide is a 
synthetic peptide which has a coumarin fluorophore (donor) at one end and a fluoroscein 
fluorophore (acceptor) at the other end. In the development (secondary) reaction, a development 
reagent which contains a site-specific protease is added. This protease does not cleave the 
phosphorylated FRET peptide, but it cleaves the non-phosphorylated FRET peptide (Figure 50). 
The emission ratio is calculated after the donor fluorophore is excited at 410 nm. 
Emission Ratio = Coumarin Emission (458 nm) / Fluoroscein Emission (522 nm) 
Cleaved peptide has a higher Emission Ratio (as the FRET between donor and acceptor 
fluorophores is lost) indicating higher inhibition of the kinase whereas uncleaved peptide has a 
lower Emission Ration (as the FRET between donor and acceptor fluorophores is maintained) 
indication lower/no inhibition of the kinase. 
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Figure 50. Z′-LYTE assay principle 
 
4.4.2 AKT1 assay results 
6 was the most potent one among the compounds tested (Table 8). This is assumed to be due to 
the pyran ring which confers rigidity to the molecule. Also, it has the Michael acceptor which 
could be alkylating the cysteine residue(s) present in the T-loop region of AKT1. A ten-fold loss 
of potency was observed in 4-61 compared to 4-46. This is probably due to the flexibility of 4-61 
which could be preventing it from making important interactions with AKT1 at its binding site. 
The compound 4-63 showed moderate potency though it was unstable in solution. The activity 
observed could be due to the rigidity of the molecule which does not get affected upon reduction. 
4-56 was found to be about four times less potent than 4-61. This could be due to the flexibility 
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of the aliphatic chain in 4-56 as compared to the closed rigid lactone ring in 4-61. The potency of 
4-52 was similar to 4-56, probably because it cannot make the necessary interactions in AKT1 at 
its binding site. The IC50 value of 4-59 was >100 µM, this could be due to the flexibility or the 
hydrophilicity of the molecule which might be unfavorable for AKT1 interaction. Also, the 
compound mainly existed as dimers and trimers (based on mass spectrum); this could prevent the 
molecule(s) from entering the binding site of the enzyme. The IC50 value obtained for 4-60 might 
not be accurate as inhibition plateaus from 4-100 µM at 50% inhibition (4-60 may exist as the 
reduced quinone in equilibrium with the oxidized form at higher concentrations). The IC50 value 
obtained for 4-54 might not be accurate as the inhibition curve does not cover the range of 0-
100% inhibition.   
 
4.4.3 Evaluation of the activity of the compounds against PKA 
The 7-deoxykalafungin analogs were evaluated as PKA inhibitors to determine what features of 
the compounds confer selectivity to AKT1 over other closely related kinases. The compounds 4-
46, 4-52, 4-54 and 4-56 had IC50 values >100 µM (Table 8). This is similar to the report of 
Wyeth researchers on PNQ lactones; they found PNQ lactones to selectively inhibit 
AKT1/AKT2 over PKA and PKC. 4-61 had an IC50 value of 0.43 µM. This is very surprising as 
the compound is not only the most potent one among the series against PKA, but also is a better 
inhibitor of PKA compared to AKT1. This could be due to the flexibility of the molecule which 
somehow makes it accessible to the binding site on PKA.  
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Table 8. AKT1 and PKA IC50 values of compounds 
No. Compound Structure AKT1 IC50 (µM) PKA IC50 (µM) 
 
4-46 
 
0.28 >100 
4-61 
 
2.94 0.43 
4-60 
 
10.98 Not tested 
 
4-56 
 
13.67 >100 
4-59 
 
>100 Not tested 
4-54 
 
50.01 >100 
4-52 
 
12.27 >100 
 66 
 
 
4.5 Synthesis of 5-alkynyl analog of 7-deoxykalafungin (4-63) 
4.5.1 Rationale  
Based on the mechanism of inhibition of AKT by PNQ lactones, it can be hypothesized that, 
inside cells, 7-deoxykalafungin would bind covalently to AKT and other cellular targets (if any) 
to form covalent complex(es). Installing an alkyne handle in 7-deoxykalafungin could be used to 
perform a ‘click reaction’ in situ between the alkynyl 7-deoxykalafungin/cellular target covalent 
complex(es) and biotin-azide (4-62) to form adduct(s) (4-64) (Figure 51). This would allow the 
isolation of the covalent complexes by affinity purification using streptavidin or avidin columns 
(which bind biotin). The covalent complex(es) could be then characterized by mass spectrometry 
after purification on SDS gels. 
According on the SAR studies on PNQ lactones inhibiting AKT, by Salaski et al, position 5 on 
the PNQ lactone tolerates a wide range of substituents. Hence, we decided to incorporate an 
alkyne functionality at position 5 in order to find out the cellular targets of PNQ lactones. Thus, 
we planned to synthesize the compound 4-63 (Figure 51). 
 
 
Figure 51. Biotin azide (4-62) and 4-63 
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Figure 52. Schematic for the identification of cellular target(s) of PNQ lactones 
 
Synthesis of 4-65 
Oxa-Pictet Spengler cyclization was carried out on 4-44 using 3-(trimethylsilyl)-2-propynal in 
dichloromethane in the presence of the Lewis acid boron trifluoride diethyl etherate. It resulted 
in the desired product 4-65 (trans relationship between 5 and 3a; 5 and 11a) in 43% yield. 
Another diastereomer was formed in about 40% yield. This shows that the stereochemistry and 
the proportion of the products formed entirely depends upon the aldehyde used.  
Synthesis of 4-66 
The trimethylsilyl group of 4-65 was deprotected to give 4-66 using tetrabutyl ammonium 
fluoride solution. The yield was low due to some degradation of the compound during the 
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reaction. The by-products were not characterized. The stereochemistry of 4-66 was the same as 
that of 4-65. 
Synthesis of 4-63 
4-66 was oxidized using ammonium cerium (IV) nitrate in water and acetonitrile mixture (1:1) to 
4-63 in 60% yield (Figure 52). The stereochemistry of 4-63 was the same as that of 4-66. The 
product 4-63 was very unstable. Within 10 min of purification on silica gel, the color of the 
product in solution changed from yellow to dark red. Due the color change, we hypothesize that 
the compound is auto-reduced in a redox reaction. Based on the NMR spectra, there were two 
compounds, whose ratio changed as a function of time. In order to find out if the compound is 
getting degraded due to the purification on silica, the reaction was repeated and the product was 
extracted with ethyl acetate and no purification was performed. Even in this case, the compound 
turned from yellow color (oxidized) to a dark red color (reduced). Thus, it was concluded that the 
product is unstable by its own nature. Upon treating the reduced product with ammonium cerium 
(IV) nitrate, it was getting re-oxidised during the course of the reaction; but again after extraction 
it was getting auto-reduced i.e. the product was stable only in the presence of ammonium cerium 
(IV) nitrate. It could be getting degraded to 4-67, 4-68 or 4-69 (Figure 53). Due to the inherent 
unstable nature of this compound (4-63), it could not be used as a cellular probe. This work 
would be continued in the near future by making similar alkynyl analogs. The IC50 of 4-63 
against AKT1 was 3.89 µM. 
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Figure 53. Synthesis of 5-alkynyl analog of 7-deoxykalafungin 4-63 
 
 
Figure 54. Proposed mechanisms for the degradation of 4-63 
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4.6 Future direction 
The future work on the compounds synthesized would be: 
- To determine the inhibition mechanism of AKT1 (allosteric/ATP competitive/peptide 
substrate competitive, etc.) 
- To find out the specific residues alkylated 
- To determine the specificity of inhibition of AKT1 over AKT2 and AKT3 
- To perform cell-based assays on cancer cell lines (for potency determination) and normal cell 
lines (for toxicity determination) 
- To synthesize an alkynyl probe (handle for 7-deoxykalafungin) to find the cellular targets of 
PNQ lactones 
 
4.7 Summary 
In summary, we successfully synthesized 7-deoxykalafungin and its deconstruction analogs. We 
hypothesize that the pyran ring is essential for AKT1 inhibition probably due to the rigidity it 
confers to the molecule. The role of the Michael acceptor in the molecules could not be 
determined for sure. Flexible compounds were found to have lower potency probably due to the 
failure to make important interactions at the binding site of AKT1. Surprisingly, compound 4-61 
was found to be a very potent inhibitor of PKA; the flexibility of this compound probably makes 
it more accessible to the binding site of PKA. 
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EXPERIMENTAL SECTION 
1. Biology experimentals 
a. AKT1 Assay 
The assay of AKT1 was performed using Z′-LYTE Kinase Assay Kit – Ser/Thr 6 Peptide 
(Invitrogen, NY, USA)  in non-binding low-volume 384-well plates (Cat. No 3676, Corning, 
NY, USA). The compounds were tested in 0.8% DMSO (final concentration) in the well. 10 
different concentrations of the compounds were tested using 3-fold serial dilutions. AKT1 was 
diluted in the kinase buffer (50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM 
EGTA) and added to the wells. The test compounds (diluted in kinase buffer) were then added 
into these wells. The kinase reaction was then started by adding a mixture containing ATP, 
peptide substrate (serine/threonine 06) and kinase buffer to the above solution. The final reaction 
volume of 10 µL contained 6 ng of AKT1 (600 ng/ml), 75 µM ATP and 2 µM peptide substrate 
in kinase buffer. The assays were incubated at room temperature for 1 h. Then 5 µL of 
development reagent was added. This mixture was incubated at room temperature for further 1 h 
and then terminated by the addition of 5 µL of stop reagent. The Relative Fluorescence Units 
(RFU) was measured using Flexstation 3 microplate reader (Molecular Devices, CA, USA) using 
an excitation wavelength of 410 nm and emission wavelengths of 458 nm and 522 nm.  
Staurosporine was used as a standard compound (Figure 54). The graphs in figures 55-57 were 
used to calculate the IC50 values against AKT1. 
 
 
 
                                              Figure 55. Staurosporine 
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Figure 56. AKT1 inhibition graphs of 4-46, 4-63, staurosporine, 4-60 and 4-61  
4-60 
 
4-63 
 
staurosporine 
 
4-61 
 
4-46 
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 Figure  57. AKT1 inhibition graphs of 4-52, 4-54 and 4-56 
4-54 
 
4-52 
 
4-56 
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Figure 58. AKT1 inhibition graph of 4-59 
Table 9. IC50 values of the compounds against AKT1 
Compound IC50 (µM) 95% Confidence Interval 
4-46 0.28 0.23-0.34 
4-63 3.89 3.26-4.65 
Staurosporine 0.011 0.007-0.017 
4-60 10.98
a 
5.52-21.82 
4-61 2.94 2.02-4.08 
4-52 12.27 10.48-14.37 
4-54 50.01
b 
35.62-70.21 
4-56 13.67 10.60-17.63 
4-59 >100 - 
 
a
 This value might not be meaningful as inhibition seems to plateau at 50% inhibition from 
around   4-100μM 
 
b
 This value might not be accurate as the inhibition curve does not span the range of 0-100% 
inhibition 
 
4-59 
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b. PKA Assay 
The assay of PKAα was performed using Z′-LYTE Kinase Assay Kit – Ser/Thr 1 Peptide 
(Invitrogen, NY, USA) in non-binding low-volume 384-well plates (Cat. No 3676, Corning, NY, 
USA). The compounds were tested in 0.8% DMSO (final concentration) in the well. 10 different 
concentrations of the compounds were tested using 3-fold serial dilutions. PKAα was diluted in 
the kinase buffer (50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA) and 
added to the wells. The test compounds (diluted in kinase buffer) were then added into these 
wells. The kinase reaction was then started by adding a mixture containing ATP, peptide 
substrate (serine/threonine 01) and kinase buffer to the above solution. The final reaction volume 
of 10 µL contained 0.3 ng of PKAα (30 ng/ml), 4 µM ATP and 2 µM peptide substrate in kinase 
buffer. The assays were incubated at room temperature for 1 h. Then 5 µL of development 
reagent A was added. This mixture was incubated at room temperature for further 1 h and then 
terminated by the addition of 5 µL of stop reagent. The Relative Fluorescence Units (RFU) was 
measured using Flexstation 3 microplate reader (Molecular Devices, CA, USA) using an 
excitation wavelength of 410 nm and emission wavelengths of 458 nm and 522 nm.  
 
Figure 59. PKA inhibition graph of staurosporine 
Staurosporine 
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Figure 60. PKA inhibition graphs of 4-46, 4-52 and 4-54 
4-46 
 
4-52 
 
4-54 
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Figure 61. PKA inhibition graphs of 4-56 and 4-61 
 
 
 
 
4-56 
 
4-61 
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Table 10. IC50 values of the compounds against PKA 
Compound IC50 (µM) 95% Confidence Interval 
Staurosporine <0.0015 - 
4-46 >100 - 
4-52 >100 - 
4-54 >100 - 
4-56 >100 - 
4-61 0.43 0.41-0.46 
(Staurosporine was used as a standard compound) 
The graphs in figures 58-60 were used to calculate the IC50 values against PKA. 
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2. Chemistry experimentals 
General methods: 
Reagents/chemicals, catalysts, solvents were purchased from Sigma-Aldrich, Fisher and Alfa-
Aesar.  
Analytical Thin Layer Chromatography (TLC) was performed using silica gel GHLF plates 
(Analtech Inc.)  
Flash chromatography was performed on TELEDYNE ISCO CombiFlash® Rf instrument using 
RediSep Rf Normal-phase Flash Columns (4-gm, 12-gm, 24-gm or 40-gm).   
1
H NMR and 
13
C NMR experiments were recorded on BRUKER 400MHz NMR instrument in 
deuterated solvents - chloroform (CDCl3) or methanol (CD3OD). All chemical shifts are reported 
in parts per million (ppm) with reference to chloroform and methanol residual peaks at 7.26 and 
3.31 respectively (
1
H NMR spectra); 77.16 and 49.00 respectively (
13
C NMR spectra).  The data 
is reported as: chemical shifts (ppm), multiplicity (s = singlet, d = doublet, dd = doublet of 
doublets, t = triplet, dt = doublet of triplets, td = triplet of doublets, tt = triplet of triplets, q = 
quartet, m = multiplet), coupling constant(s) (Hz) and integral values. 
 
 
 
2-bromo-1,4-dimethoxynaphthalene (4-42): 1,4-dimethoxynaphthalene (1.00 g, 5.31 mmol) 
was dissolved in anhydrous DCM (7.48 ml). To this solution, N-bromosuccinimide (0.95 g, 5.34 
mmol) was added. The reaction mixture was stirred at room temperature for 18 h. It was then 
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diluted with DCM. The organic layer was washed with saturated sodium sulfite solution, dried 
over Na2SO4, concentrated in vacuo and purified on silica gel (3:1 hexanes/EtOAc) to afford 
1.37 g of 4-42 (96%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 8.20 (d, J = 8.2 Hz, 1H), 
8.08 (d, J = 8.2 Hz, 1H), 7.59-7.48 (m, 2H), 6.88 (s, 1H), 3.98 (s, 3H), 3.96 (s, 3H).  
 
 
 
(E)-isobutyl 4-(1,4-dimethoxynaphthalen-2-yl)but-3-enoate (4-43): Under an atmosphere of 
argon, compound 4-42 (1.32 g, 4.96 mmol) was dissolved in 5.69 ml of anhydrous toluene 
(which was passed over molecular sieves and degassed prior to use). To this solution, isobutyl 
vinylacetate (1.80 ml, 11.26 mmol), dicyclohexylmethylamine (1.64 ml, 7.66 mmol) and bis(tri-
tert-butylphosphine)palladium (0.14 g, 0.28 mmol) were added. The reaction mixture was heated 
at 110 
o
C under argon for 16 h. It was then quenched with aqueous NaHCO3 solution and 
extracted with EtOAc. The organic layer was dried over Na2SO4 and evaporated. Purification of 
the residue on silica gel (5:1 hexanes/EtOAc) afforded 1.32 g (81%) of 4-43 as a brown viscous 
liquid. 
1
H NMR  (400 MHz, CDCl3) δ 8.20 (d, J = 8.6 Hz, 1H), 8.05 (d, J = 8.1 Hz, 1H), 7.56-
7.42 (m, 2H), 7.04-6.98 (dt, J = 16.2 Hz, 1H), 6.89 (s, 1H), 6.45-6.37 (m, 1H), 4.01 (s, 3H), 4.0-
3.9 (m, 2H), 3.88 (s, 3H), 3.40-3.36 (dd, J  = 7.3 Hz, 2H), 2.00 (m, 1H), 0.96 (s, 3H), 0.95 (s, 
3H); 
13
C NMR (125 MHz, CDCl3) δ 128.9, 128.2, 126.9, 125.7, 124.9, 122.8, 122.6, 122.3, 
100.8, 71.0, 62.6, 55.8, 38.9, 27.9, 19.2.  
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(4R,5R)-5-(1,4-dimethoxynaphthalen-2-yl)-4-hydroxydihydrofuran-2(3H)-one (4-44): A 
round bottom flask was charged with potassium ferricyanide (III) (4.53 g, 13.74 mmol), 
potassium carbonate (1.86 g, 13.47 mmol), hydroquinidine 1,4-phthalazinediyl diether (0.03 g, 
0.04 mmol), potassium osmate dihydrate (9.00 mg, 0.02 mmol), methanesulfonamide (0.44 g, 
4.67 mmol), sodium bicarbonate (1.03 g, 12.27 mmol), water (24.00 ml) and tert-butanol (9.00 
ml). This mixture was stirred at room temperature till all the solids dissolved. It was then cooled 
to 0 °C. To this mixture was added a solution of 4-43 (1.34 g, 4.09 mmol) in tert-butanol (15.00 
ml) in one portion. The resulting turbid mixture was stirred at 0 °C for 24 h and then room 
temperature for 3 days. The reaction was quenched by the addition of sodium sulfite (4.27 g, 
33.90 mmol) in one portion and was allowed to stir for 1 hr at room temperature. It was extracted 
with EtOAc and concentrated in vacuo. It was observed that under these conditions, the 
lactonization was not fully completed. In order to facilitate complete lactonization, the crude 
product obtained above was treated with 40 ml of 0.1 N NaOH solution and stirred at room 
temperature for 2 h. This resulted in the cleavage of the isobutyl ester to form the acid. The 
reaction mixture was then acidified with 14 ml of 3 N hydrochloric acid. To this mixture, p-
toluenesulfonic acid monohydrate (0.08 g, 0.40 mmol) in DCM (14.00 ml) was added and 
allowed to stir at room temperature for 24 h. The reaction mixture was then extracted with DCM, 
washed with brine and aqueous NaHCO3 solution. The organic layer was dried over Na2SO4 and 
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evaporated. Purification of the residue on silica gel (1:3 hexanes/EtOAc) afforded 0.62 g (53%) 
of 4-44 as a white solid (d.r. >95:5). 
1
H NMR  (400 MHz, CDCl3) δ 8.28 (d, J = 8.7 Hz, 1H), 
8.01 (d, J = 8.3 Hz, 1H), 7.60-7.46 (m, 2H), 6.88 (s, 1H), 5.90 (d, J =  3.7 Hz, 1H), 4.84 (t, J =  
4.3 Hz, 1H), 4.0 (s, 3H), 3.92 (s, 3H), 2.98-2.90 (dd, J  = 18.1 Hz, 1H), 2.77-2.71 (d, J = 18.1 
Hz, 1H); 
13
C NMR (125 MHz, CDCl3) δ 175.5, 152.7, 146.4, 128.1, 127.2, 127.0, 126.3, 122.9, 
121.8, 102.0, 82.1, 70.0, 62.4, 56.1, 38.4. 
 
 
 
(3aR,5R,11bR)-6,11-dimethoxy-5-methyl-3,3a,5,11b-tetrahydro-2H-benzo[g]furo[3,2-
c]isochromen-2-one (4-45): Compound 4-44 (0.10 g, 0.34 mmol) was dissolved in anhydrous 
DCM (3.45 ml). To this solution, acetaldehyde (0.02 ml, 0.38 mmol) was added. The reaction 
mixture was cooled to 0 
o
C. To it, boron trifluoride diethyl etherate (0.04 ml, 0.36 mmol) was 
added drop wise. The reaction was allowed to warm to room temperature overnight. It was then 
quenched with saturated aqueous sodium bicarbonate solution, extracted with DCM. The organic 
layer was dried over Na2SO4, concentrated in vacuo and purified on silica gel (3:1 
hexanes/EtOAc) to yield 0.10 g (d.r. >95:5) of 4-45 (93%). 
1
H NMR  (400 MHz, CDCl3)  δ 8.10 
(d, J = 8.6 Hz, 1H), 8.03 (d, J = 8.3 Hz, 1H), 7.58-7.50 (m, 2H), 5.60 (d, J =  2.6 Hz, 1H), 5.35 
(q, J =  6.8 Hz, 1H), 4.7 (q, J = 2.8, 2.0 Hz, 1H), 4.08 (s, 3H), 3.93 (s, 3H), 3.00 (dd, J  = 17.8, 
1H), 2.70 (d, J = 17.5 Hz, 1H), 1.53 (d, J =  6.7 Hz, 3H). 
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(3aR,5R,11bR)-5-methyl-3,3a-dihydro-2H-benzo[g]furo[3,2-c]isochromene-
2,6,11(5H,11bH)-trione (4-46): Compound 4-45 (0.10 g, 0.32 mmol) was dissolved in 
acetonitrile (6.8 ml). This solution was cooled to 0 
o
C. To this, a solution of cerium ammonium 
nitrate (0.41 g, 0.74 mmol) in water (6.8 ml) was added at once. The reaction mixture was stirred 
at 0 
o
C for 30 min. It was then quenched with ethyl acetate and water. The organic phase was 
washed several times till it was free from the cerium salt. It was then dried over Na2SO4, 
concentrated in vacuo and purified on silica gel (3:1 hexanes/EtOAc) to afford 0.07 g of 4-46 
(71%) as a yellow solid. 
1
H NMR  (400 MHz, CDCl3)  δ 8.18-8.15 (m, 1H), 8.13-8.10 (m, 1H), 
7.82-7.76 (m, 2H), 5.29 (d, J = 3.0 Hz, 1H), 5.12-5.06 (q, J = 7.0 Hz, 1H), 4.70-4.68 (q, J = 3.0 
Hz, 2.1 Hz, 1H), 3.00-2.92 (dd, J = 17.6 Hz, 1H), 2.70 (d, J = 17.6, 1H), 1.54 (d, J = 6.7 Hz, 
3H); 
13
C NMR (125 MHz, CDCl3) δ 183.2, 182.4, 174.0, 149.6, 134.6, 134.4, 134.3, 132.0, 
131.9, 127.0, 126.7, 68.9, 66.7, 66.6, 37.1, 18.7. 
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N-methoxy-N-methylbenzamide (4-51):
93
 Benzoic acid (1.2 g, 9.81 mmol) was dissolved in 
DCM (24.54 ml). To this 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (2.25 
g, 11.79 mmol) and N-methyl morpholine (1.08 ml, 9.81 mmol) followed by N,O-
Dimethylhydroxylamine hydrochloride (1.05 g, 10.8 mmol) were added. The reaction mixture 
was stirred at room temperature for 4 h. It was diluted with diethyl ether. The organic layer was 
washed with water and brine, dried over Na2SO4, concentrated in vacuo and purified on silica gel 
(3:1 hexanes/EtOAc) to afford 1.36 g of 4-51 (84%) as a colorless oil. 
1
H NMR  (400 MHz, 
CDCl3) δ 7.67-7.64 (d, J = 7.7 Hz, 2H), 7.45-7.35 (m, 3H), 3.55 (s, 3H), 3.35 (s, 3H); 
13
C NMR 
(125 MHz, CDCl3) δ 170.0, 134.3, 130.6, 128.2, 128.1, 61.1, 33.9. 
 
 
 
1-phenylprop-2-en-1-one (4-52):
94
 N-methoxy-N-methylbenzamide (0.1 g, 0.60 mmol) was 
dissolved in anhydrous diethyl ether (2.01 ml). The solution was cooled to 0 
o
C. To this, vinyl 
magnesium bromide solution (0.91 ml, 1.0 M in THF) was added drop wise over 30 min at 0 
o
C. 
After the completion of addition, the reaction mixture was stirred for a further 60 min at 0 
o
C and 
for 30 min at room temperature. It was then quenched with 1M HCl at 0 
o
C. The reaction mixture 
was diluted with diethyl ether. The organic layer was washed with brine, dried over Na2SO4, 
concentrated in vacuo, purified on silica gel (3:1 hexanes/EtOAc) to afford 0.04 g of 4-52 (55%) 
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as a colorless oil. 
1
H NMR  (400 MHz, CDCl3) δ 7.96-7.93 (d, J = 8.3 Hz, 2H), 7.60-7.55 (tt, J = 
7.4 Hz, 1H), 7.51-7.46 (t, J = 8.0 Hz, 2H), 7.20-7.10 (q, J = 10.5 Hz, 6.6 Hz, 1H), 6.40 (dd, J = 
17.1 Hz, 1H), 5.90 (dd, J = 10.6 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) δ 191.2, 137.5, 133.1, 
132.6, 130.2, 128.8, 128.7. 
 
 
 
(E)-4-methoxy-1-phenylbut-2-en-1-one (4-54):
95
 1-phenylprop-2-en-1-one (0.23 g, 1.73 mmol) 
and 3-methoxyprop-1-ene (0.05 g, 0.69 mmol) were dissolved in anhydrous DCM (3.46 ml) 
under argon. To this solution, the cross-metathesis catalyst [CAS number 253688-91-4 (0.02 g, 
0.02 mmol)] was added. The reaction mixture was refluxed overnight (maintaining the 
temperature below 42 
o
C) under argon. It was then cooled to room temperature, concentrated in 
vacuo and purified on silica gel (3:1 hexanes/EtOAc) to afford 0.04 g of 4-54 (30%) as a brown 
oil (E:Z >20:1). 
1
H NMR  (400 MHz, CDCl3) δ 7.99-7.95 (d, J = 8.3 Hz, 2H), 7.59-7.54 (tt, J = 
7.4 Hz, 1H), 7.50-7.45 (tt, J = 7.7 Hz, 2H), 7.20-7.14 (dt, J = 15.5, 1H), 7.08-7.01(dt, J = 15.5 
Hz, 1H), 4.20 (q, J = 2.0 Hz, 1.8 Hz, 2H), 3.46 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 190.4, 
144.4, 137.8, 133.0, 128.8, 128.7, 124.9, 71.8, 58.9. 
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Methyl pent-4-enoate (4-55):
96
 Pent-4-enoic acid (0.83 g, 8.29 mmol) and potassium carbonate 
(5.69 g, 41.17 mmol) were dissolved in acetone (8.16 ml). To this suspension, iodomethane (2.55 
ml, 40.96 mmol) was added drop wise at room temperature. This suspension was refluxed at 60 
o
C overnight. The reaction mixture was cooled to room temperature, diluted with diethyl ether. 
The organic layer was washed with ammonium chloride solution, dried over Na2SO4, 
concentrated at reduced pressure to afford 0.54 g of 4-55  (57%) as a colorless oil. 
1
H NMR  
(400 MHz, CDCl3) δ 5.86-5.76 (m, 1H), 5.08-4.95 (m, 2H), 3.67 (s, 3H), 2.43-2.36 (m, 4H); 
13
C 
NMR (125 MHz, CDCl3) δ 173.6, 136.8, 115.6, 51.6, 33.5, 28.9. 
 
 
 
 (E)-methyl 6-oxo-6-phenylhex-4-enoate (4-56):
95 1-phenylprop-2-en-1-one (0.28 g, 2.18 
mmol) and Methyl pent-4-enoate (0.10 g, 0.88 mmol) were dissolved in anhydrous DCM (4.38 
ml) under argon. To this solution, the cross-metathesis catalyst [CAS number 253688-91-4  (30 
mg, 0.04 mmol)] was added. The reaction mixture was refluxed overnight under argon. It was 
then cooled to room temperature, concentrated in vacuo and purified on silica gel (3:1 
hexanes/EtOAc) to afford 0.08 g of 4-56 (41%) as a brown oil (E:Z >20:1). 
1
H NMR  (400 MHz, 
CDCl3) δ 7.9 (d, J = 8.3 Hz, 2H), 7.55 (t, J = 7.3 Hz, 1H), 7.45 (t, J = 7.8 Hz, 7.3 Hz, 2H), 7.0 
(m, 1H), 6.9 (dt, J = 15.5 Hz, 1H), 3.7 (s, 3H), 2.6 (q, J = 7.0 Hz, 2H), 2.5 (t, J = 7.0 Hz, 2H); 
13
C 
NMR (125 MHz, CDCl3) δ 190.6, 172.8, 146.8, 137.9, 132.8, 128.6, 126.8, 51.8, 32.6, 27.9. 
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tert-butyl pent-4-enoate (4-57):
97
 Pent-4-enoic acid (0.10 g, 0.99 mmol) was dissolved in DCM 
(0.49 ml). To this solution, t-butanol (0.38 ml, 0.29 mmol) and 4-DMAP (1.95 mg, 0.01 mmol) 
were added. This mixture was cooled to 0 
o
C. Then, N,N'-Dicyclohexylcarbodiimide (0.22 g, 
1.09 mmol) was added. The reaction mixture was stirred at 0 
o
C for 15 min and at room 
temperature for 20 h. The reaction mixture was filtered through celite. The organic layer was 
washed with 0.1 M HCl, saturated aqueous sodium bicarbonate solution and water. It was dried 
over Na2SO4, concentrated in vacuo and purified on silica gel (3:1 hexanes/EtOAc) to afford 0.06 
g of 4-57 (40%) as a colorless oil. 
1
H NMR  (400 MHz, CDCl3) δ 5.86-5.76 (m, 1H), 5.08-4.96 
(m, 2H), 2.36-2.27 (m, 4H), 1.44 (s, 9H); 
13
C NMR(125 MHz, CDCl3) δ 172.5, 137.1, 115.3, 
80.3, 55.9, 34.9, 29.2, 28.3, 25.6, 24.8, 21.9. 
 
 
(E)-tert-butyl 6-oxo-6-phenylhex-4-enoate (4-58):
95
 1-phenylprop-2-en-1-one (0.11 g, 0.80 
mmol) and tert-butyl pent-4-enoate (0.05 g, 0.32 mmol) were dissolved in anhydrous DCM (1.6 
ml) under argon. To this solution, the cross-metathesis catalyst [CAS number 253688-91-4   
(0.01 g, 0.01 mmol)] was added. The reaction mixture was refluxed overnight under argon. It 
was then cooled to room temperature, concentrated in vacuo and purified on silica gel (EtOAc : 
hexanes = 1 : 3) to afford 0.04 g of 4-58 (46%) as a brown oil (E:Z >20:1). 
1
H NMR  (400 MHz, 
CDCl3) δ 7.9 (d, J = 8.4 Hz, 2H), 7.57-7.52 (tt, J = 7.4 Hz, 1H), 7.48-7.42 (tt, J = 7.7 Hz, 2H), 
7.06-6.99 (m, 1H), 6.94-6.88 (dt, J = 15.5 Hz, 1H), 2.63-2.57 (q, J = 6.9 Hz, 2H), 2.48-2.42 (t, J 
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= 7.3 Hz, 2H), 1.47 (s, 9H); 
13
C NMR (125 MHz, CDCl3)  δ 190.7, 171.7, 147.5, 138.0, 132.8, 
128.7, 126.7, 80.9, 53.5, 34.0, 28.2. 
 
 
 
(E)-6-oxo-6-phenylhex-4-enoic acid (4-59):
98
 (E)-tert-butyl 6-oxo-6-phenylhex-4-enoate (0.03 
g, 0.13 mmol) was dissolved in anhydrous DCM (1.26 ml). To this solution, triethylsilane (0.05 
ml, 0.31 mmol) was added followed by the drop wise addition of trifluoroacetic acid (0.09 ml, 
1.18 mmol). The reaction mixture was stirred at room temperature for 6 h. The solvent was 
concentrated in vacuo and the crude product was purified on silica gel (1:20 methanol/DCM) to 
afford 0.01 g of 4-59 (36%) as a white solid. There was another product formed during this 
reaction which tailed on TLC plate in 40% EtOAc-hexanes (Rf = 0.3) solvent system, but it could 
not be characterized by NMR data. Based on the mass spectrum, a majority of this compound 4-
59 was found to exist as dimers, and the minor portion consisted of trimers and monomers. 
1
H 
NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.3 Hz, 2H), 7.68-7.62 (tt, J = 7.3 Hz, 1H), 7.52 (t, J = 
7.9 Hz, 7.4 Hz, 2H), 5.16-5.08 (m, 1H), 3.65-3.57 (dd, J = 17.4 Hz, 1H), 3.42-3.35 (dd, J = 17.5 
Hz, 1H), 2.65-2.50 (m, 3H), 2.09-1.98 (m, 1H); 
13
C NMR (125 MHz, CDCl3)  δ 134.6, 129.8, 
129.2, 78.7, 44.7, 29.4. 
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Naphthalene-1,4-dione (4-60): 1,4-dimethoxynaphthalene (0.05 g, 0.26 mmol) was dissolved in 
acetonitrile (5.3 ml). This solution was cooled to 0 
o
C. To this, a solution of cerium ammonium 
nitrate (0.34 g, 0.61 mmol) in water (5.3 ml) was added at once. The reaction mixture was stirred 
at 0 
o
C for 30 min. It was then quenched with ethyl acetate and water. The organic phase was 
washed several times till it was free from the cerium salt. It was then dried over Na2SO4, 
concentrated in vacuo and purified on silica gel (3:1 hexanes/EtOAc) to afford 0.03 g of 4-60 
(81%) as a yellow solid. 
1
H NMR  (400 MHz, CDCl3) δ 8.12-8.07 (m, 2H), 7.79-7.74 (m, 2H), 
7.00 (s, 2H); 
13
C NMR (125 MHz, CDCl3) δ 138.8, 134.1, 132.1, 126.6. 
 
 
 
2-((2R,3R)-3-hydroxy-5-oxotetrahydrofuran-2-yl)naphthalene-1,4-dione (4-61):  (4R,5R)-5-
(1,4-dimethoxynaphthalen-2-yl)-4-hydroxydihydrofuran-2(3H)-one (0.04 g, 0.12 mmol) was 
dissolved in acetonitrile (2.4 ml). This solution was cooled to 0 
o
C. To this, a solution of cerium 
ammonium nitrate (0.15 g, 0.28 mmol) in water (2.4 ml) was added at once. The reaction 
mixture was stirred at 0 
o
C for 30 min. It was then quenched with ethyl acetate and water. The 
organic phase was washed several times till it was free from the cerium salt. It was then dried 
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over Na2SO4, concentrated in vacuo and purified on silica gel (1:1 hexanes/EtOAc) to afford 
0.02 g of 4-61 (65%) as a yellowish-brown solid. 
1
H NMR  (400 MHz, CDCl3) δ 8.13-8.08 (td, 
6.87 Hz,7.0 Hz, 2H), 7.82-7.76 (m, 2H), 7.17 (d, J = 1.9 Hz, 1H), 5.60 (dd, J = 4.2 Hz, 1H), 5.07 
(t, J = 5.1 Hz, 1H), 3.02-2.95 (dd, J = 18 Hz, 1H), 2.72-2.66 (d, J = 17.8 Hz, 1H); 
13
C NMR (125 
MHz, CDCl3) δ 184.8, 184.1, 173.8, 143.8, 135.6, 134.6, 134.1, 132.2, 131.8, 126.7, 126.5, 80.6, 
69.5, 38.6. 
 
 (3aR,5S,11bR)-6,11-dimethoxy-5-((trimethylsilyl)ethynyl)-3,3a,5,11b-tetrahydro-2H-
benzo[g]furo[3,2-c]isochromen-2-one (4-65): Compound 4-46 (0.30 g, 1.04 mmol) was 
dissolved in anhydrous DCM (10.34 ml). To this solution, 3-(trimethylsilyl)propiolaldehyde 
(0.17 ml, 1.14 mmol) was added. The reaction mixture was cooled to 0 
o
C. To it, boron 
trifluoride diethyl etherate (0.13 ml, 1.05 mmol) was added drop wise. The reaction was allowed 
to warm to room temperature overnight. It was then quenched with saturated aqueous sodium 
bicarbonate solution, extracted with DCM. The organic layer was dried over Na2SO4, 
concentrated in vacuo and purified on silica gel (3:1 hexanes/EtOAc) to yield 0.18 g (d.r. 1:1) of 
4-65 (43%),. About 40% of another diastereomer was formed. 
1
H NMR  (400 MHz, CDCl3)  δ 
8.16-8.13 (dd, J = 8.0 Hz, 1H), 8.10-8.07 (dd, J = 6.8 Hz, 1H), 7.62-7.54 (m, 2H), 6.05 (s, 1H), 
5.63 (d, J =  2.8 Hz, 1H), 5.07-5.04 (q, J =  2.9 Hz, 2.3 Hz, 1H), 4.15 (s, 3H), 4.05 (s, 3H), 3.08-
3.00 (dd, J  = 17.7, 1H), 2.80 (d, J = 17.9 Hz, 1H), 0.13 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 
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174.9, 153.8, 148.1, 129.3, 128.5, 127.4, 126.6, 123.7, 123.3, 122.8, 117.5, 102.4, 92.9, 72.3, 
68.8, 64.4, 62.4, 62.3, 37.5. 
 
 
 
(3aR,5R,11bR)-5-ethynyl-6,11-dimethoxy-3,3a,5,11b-tetrahydro-2H-benzo[g]furo[3,2-
c]isochromen-2-one (4-66): Compound 4-65 (0.18 g, 0.45 mmol) was dissolved in 
tetrahydrofuan (4.02 ml). To this solution, tetrabutylammoniumflouride solution (0.49 ml, 1.0 M 
in THF) was added. The reaction mixture was stirred at room temperature for 1 h. The organic 
layer was washed with saturated aqueous ammonium chloride solution, extracted with DCM. 
The DCM layer was dried over Na2SO4, concentrated in vacuo and purified on silica gel (3:1 
hexanes/EtOAc to yield 0.07 g of 4-66 (44%). A major quantity of the starting material was 
degraded during the reaction resulting in low yield of the desired product. 
1
H NMR  (400 MHz, 
CDCl3)  δ 8.16-8.13 (dd, J = 7.9 Hz, 1H), 8.11-8.07 (dd, J = 8.0 Hz, 1H), 7.63-7.55 (m, 2H), 
6.03 (d, J = 2.3 Hz, 1H), 5.64 (d, J =  2.8 Hz, 1H), 5.09-5.06 (q, J =  3.0 Hz, 2.4 Hz, 1H), 4.12 
(s, 3H), 4.05 (s, 3H), 3.08-3.01 (dd, J  = 17.9, 1H), 2.82-2.77 (d, J = 17.8 Hz, 1H), 2.61 (d, J =  
2.3 Hz, 1H).  
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(3aR,5R,11bR)-5-ethynyl-3,3a-dihydro-2H-benzo[g]furo[3,2-c]isochromene-
2,6,11(5H,11bH)-trione (4-63): Compound 4-66 (0.07 g, 0.20 mmol) was dissolved in 
acetonitrile (4.26 ml). This solution was cooled to 0 
o
C. To this, a solution of cerium ammonium 
nitrate (0.25 g, 0.46 mmol) in water (4.26 ml) was added at once. The reaction mixture was 
stirred at 0 
o
C for 30 min. It was then quenched with ethyl acetate and water. The organic phase 
was washed several times till it was free from the cerium salt. It was then dried over Na2SO4, 
concentrated in vacuo and purified on silica gel (3:1 hexanes/EtOAc) to afford 0.03 g of 4-63 
(60%) as a yellow unstable solid. 
1
H NMR  (400 MHz, CDCl3)  δ 8.20-8.13 (m, 2H), 7.85-7.80 
(m, 2H), 5.69 (d, J = 2.4 Hz, 1H), 5.29 (d, J = 3.1 Hz, 1H), 4.96-4.93 (q, J = 3.3 Hz, 3.1 Hz, 2.1 
Hz, 1H), 3.05-2.99 (dd, J = 18.0 Hz, 1H), 2.80-2.76 (d, J = 17.9, 1H), 2.64 (d, J = 2.3 Hz, 1H). 
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